[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 90 of about 90
1. Derwinger K, Gustavsson B: A study of lymph node ratio in stage IV colorectal cancer. World J Surg Oncol; 2008;6:127
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of lymph node ratio in stage IV colorectal cancer.
  • BACKGROUND: The finding of metastasis in colorectal cancer, stage IV disease, has a major impact on prognosis and treatment strategy.
  • The lymph node factors are of known importance in earlier cancer stages but less described in metastatic disease.
  • The aim of the study was to evaluate lymph node status and ratio as prognostic markers in stage IV colorectal cancer.
  • METHODS: The study was retrospective and assessing all patients operated, with bowel resection, for an initial stage IV colorectal cancer during 1999-2003 (n = 136).
  • The analysis was made by LNR group and by eligibility for chemotherapy with cancer specific survival as outcome parameter.
  • CONCLUSION: Stage IV colorectal cancer is a heterogeneous group regarding the survival prognosis.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Surg Oncol Clin N Am. 2006 Jan;15(1):129-46 [16389154.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4828-33 [18711170.001]
  • [Cites] Eur J Surg Oncol. 2008 Jul;34(7):771-5 [18079086.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1301-10 [17486358.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):735-40 [17400418.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1712-7 [17253102.001]
  • [Cites] Colorectal Dis. 2007 May;9(4):290-301 [17432979.001]
  • [Cites] Colorectal Dis. 2007 Mar;9(3):253-7 [17298624.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):20-8 [15631916.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1689-93 [15532806.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Acta Oncol. 2001;40(2-3):282-308 [11441937.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Surg Endosc. 2006 Apr;20 Suppl 2:S475-8 [16544060.001]
  • [Cites] Oncology (Williston Park). 2006 May;20(6):579-87; discussion 588, 594, 596 passim [16773844.001]
  • [Cites] Ann Thorac Surg. 2006 Jul;82(1):254-60 [16798225.001]
  • [Cites] Dis Colon Rectum. 2006 Jul;49(7):982-92 [16625329.001]
  • [Cites] Korean J Radiol. 2007 Jan-Feb;8(1):57-63 [17277564.001]
  • (PMID = 19046414.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2633268
  •  go-up   go-down


2. Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Yamaue H: Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1377-83
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer.
  • BACKGROUND: The prognosis of patients with colorectal cancer is considered to be affected by several factors.
  • In this study, the potential predictors, including chemotherapy regimens for survival after surgery, in patients with stage IV colorectal cancer are presented.
  • PATIENTS AND METHODS: Univariate and multivariate analyses of potential predictors of survival after surgery were carried out for 56 patients with stage IV colorectal cancer who had undergone surgery, including 22 with rectal and 34 with colon cancer.
  • CONCLUSION: Five factors, namely lymph node metastasis, bone metastasis, peritoneal invasion, primary liver resection and chemotherapy, are potential predictors of survival after surgery for patients with stage IV colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619547.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Ballian N, Mahvi DM, Kennedy GD: Colonoscopic findings and tumor site do not predict bowel obstruction during medical treatment of stage IV colorectal cancer. Oncologist; 2009 Jun;14(6):580-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonoscopic findings and tumor site do not predict bowel obstruction during medical treatment of stage IV colorectal cancer.
  • BACKGROUND: In the absence of symptoms related to their primary tumor, patients with stage IV colorectal cancer can undergo medical treatment with their primary tumor in situ.
  • Inclusion criteria were presentation with stage IV colorectal cancer without previous treatment.
  • CONCLUSION: In stage IV colorectal cancer, circumferential, near-obstructing lesions and inability to advance the colonoscope beyond the primary tumor are common colonoscopic findings and are associated with obstructive symptoms at the time of diagnosis.
  • [MeSH-major] Colonoscopy. Colorectal Neoplasms / complications. Intestinal Obstruction / diagnosis


Advertisement
4. Obeidat NA, Pradel FG, Zuckerman IH, Trovato JA, Palumbo FB, DeLisle S, Mullins CD: Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care; 2010 Jul;16(7):515-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer.
  • OBJECTIVES: To test the hypotheses that African American patients and older patients with stage IV colorectal cancer were less likely to receive newer chemotherapy agents.
  • METHODS: Among 5068 Surveillance, Epidemiology, and End Results-Medicare patients diagnosed as having stage IV colorectal cancer between 2000 and 2002, a total of 2466 received chemotherapy and were included in the analysis.
  • CONCLUSIONS: Disparities in chemotherapy selection exist among patients receiving chemotherapy for stage IV colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / ethnology. Continental Population Groups. Ethnic Groups. Healthcare Disparities

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645667.001).
  • [ISSN] 1936-2692
  • [Journal-full-title] The American journal of managed care
  • [ISO-abbreviation] Am J Manag Care
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / K01 AG022011
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Watkins DJ, Chau I, Cunningham D, Mudan SS, Karanjia N, Brown G, Ashley S, Norman AR, Gillbanks A: Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. Br J Cancer; 2010 Jan 19;102(2):255-61
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
  • BACKGROUND: Stage IV colorectal cancer encompasses a broad patient population in which both curative and palliative management strategies may be used.
  • In a phase II study primarily designed to assess the efficacy of capecitabine and oxaliplatin, we were able to prospectively examine the outcomes of patients with stage IV colorectal cancer according to the baseline resectability status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / surgery. Neoplasm Staging / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jan;243(1):1-7 [16371728.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):798-805 [16508637.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2702-6 [16782909.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1728-43 [16815701.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10):1261-8 [16947009.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4983-90 [17075116.001]
  • [Cites] World J Gastroenterol. 2006 Nov 21;12(43):6961-5 [17109517.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):786-94 [17103254.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1037-42 [17353923.001]
  • [Cites] Curr Oncol Rep. 2007 May;9(3):193-201 [17430690.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] Surg Oncol. 2007 Jul;16(1):71-83 [17532622.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2037-45 [17766104.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):806-14 [17968173.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] World J Surg. 2008 Jan;32(1):93-103 [18027020.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):125-35 [18156932.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):282-7 [18216534.001]
  • [Cites] Oncologist. 2008 Jan;13(1):51-64 [18245012.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1720-6 [18550577.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4828-33 [18711170.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1759-66 [11919232.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Eur J Surg Oncol. 1990 Aug;16(4):360-5 [2379594.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2 [8857855.001]
  • [Cites] Int Surg. 1998 Oct-Dec;83(4):340-2 [10096757.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):58-65 [16372158.001]
  • (PMID = 20087355.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2816665
  •  go-up   go-down


6. Cameron S, Hünerbein D, Mansuroglu T, Armbrust T, Scharf JG, Schwörer H, Füzesi L, Ramadori G: Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy. BMC Cancer; 2009;9:218
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy.
  • BACKGROUND: The treatment of the primary tumor in advanced metastatic colorectal cancer (CRC) is still a matter of discussion.
  • Little attention has thus far been paid to the endoscopically observable changes of the primary in non-curatively resectable stage IV disease.
  • CONCLUSION: This study shows that modern anti-cancer drugs combined with endoscopic therapy are an effective and safe treatment of the symptomatic primary and ameliorate local complaints without the need for surgical intervention in advanced UICC stage IV CRC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Endoscopy / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] BMC Cancer. 2008;8:120 [18439246.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Br J Radiol. 2001 Nov;74(887):983-6 [11709461.001]
  • [Cites] Abdom Imaging. 2002 Sep-Oct;27(5):570-7 [12173001.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3475-84 [15337795.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1311-9 [15870084.001]
  • [Cites] J Natl Compr Canc Netw. 2005 Jul;3(4):468-91 [16038639.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Endoscopy. 2005 Dec;37(12):1232-6 [16329023.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):668-74 [16446339.001]
  • [Cites] Br J Surg. 2006 Jul;93(7):872-8 [16671066.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):766-70 [17103261.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):428-32 [17374832.001]
  • [Cites] BMC Gastroenterol. 2007;7:14 [17391506.001]
  • [Cites] BMC Cancer. 2007;7:91 [17537235.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):625-33 [17613424.001]
  • [Cites] World J Gastroenterol. 2007 Jul 28;13(28):3806-15 [17657834.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):752-8 [17594712.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10736-43 [18006816.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5225-32 [18024868.001]
  • [Cites] Clin Colorectal Cancer. 2007 Nov;6(10):710-5 [18039424.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2007 Nov;19(11):988-94 [18049169.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):2000-5 [17785765.001]
  • [Cites] Digestion. 2008;77 Suppl 1:13-22 [18204257.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2008;22(2):295-312 [18346685.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1443-51 [18349394.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • (PMID = 19570230.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2709904
  •  go-up   go-down


7. Abdel-Misih SR, Schmidt CR, Bloomston PM: Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol; 2009;7:72
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases.
  • BACKGROUND: The management of stage IV colorectal cancer with liver metastases has historically involved a multidisciplinary approach.
  • In the last several decades, there have been great strides made in the therapeutic options available to treat these patients with advancements in medical, surgical, locoregional and adjunctive therapies available to patients with colorectal liver metastases(CLM).
  • CONCLUSION: Improvements in modern day chemotherapy as allowed clinicians to pursue a more aggressive surgical approach in the management of stage IV colorectal cancer with CLM.
  • As a result, the management of patients with CLM requires a comprehensive, multidisciplinary approach utilizing various modalities and a more aggressive approach may now be pursued in patients with stage IV colorectal cancer with CLM to achieve optimal outcomes.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Patient Care Team

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):559-65; discussion 565-7 [17893492.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4575-80 [17925551.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3481-91 [17805933.001]
  • [Cites] Clin Colorectal Cancer. 2007 Nov;6(10):710-5 [18039424.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):144-57 [17906898.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Am J Surg. 2008 Apr;195(4):508-20 [18361927.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):683-8 [18471041.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3672-80 [18669451.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2757-64 [18618182.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2765-72 [18636296.001]
  • [Cites] World J Surg Oncol. 2008;6:93 [18764938.001]
  • [Cites] Surg Oncol. 2008 Dec;17(4):295-9 [18472417.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):626-37 [18936576.001]
  • [Cites] Dig Surg. 2008;25(6):421-9 [19212114.001]
  • [Cites] Dig Surg. 2008;25(6):430-5 [19212115.001]
  • [Cites] Dig Surg. 2008;25(6):445-60 [19212117.001]
  • [Cites] Dig Surg. 2008;25(6):461-6 [19212118.001]
  • [Cites] Ann Oncol. 2009 Jun;20(6):985-92 [19153115.001]
  • [Cites] J Am Coll Surg. 2009 May;208(5):842-50; discussion 850-2 [19476847.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):879-86 [19474695.001]
  • [Cites] Lancet Oncol. 2009 Jun;10(6):559-68 [19482548.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2138-46 [19495884.001]
  • [Cites] Ann Surg Oncol. 2009 Sep;16(9):2411-21 [19554376.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):487-99 [10749608.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 2000 May;231(5):743-51 [10767796.001]
  • [Cites] Surgery. 2000 May;127(5):512-9 [10819059.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] J Gastrointest Surg. 2001 May-Jun;5(3):294-302 [11360053.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] J Gastrointest Surg. 2002 Mar-Apr;6(2):255-63 [11992812.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] Am J Surg. 2003 Mar;185(3):221-9 [12620560.001]
  • [Cites] Ann Surg Oncol. 2003 May;10(4):338-47 [12734080.001]
  • [Cites] Br J Surg. 2003 May;90(5):567-74 [12734864.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):243-55 [12735142.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1240-3 [14515293.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):114-21 [14714186.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Eur J Surg Oncol. 2004 Sep;30(7):759-64 [15296990.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):727-31 [3756436.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):1-4 [3366020.001]
  • [Cites] Surgery. 1990 May;107(5):521-7 [2333592.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Hepatology. 1995 May;21(5):1317-21 [7737637.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):59-71 [7740812.001]
  • [Cites] World J Surg. 1998 Apr;22(4):399-404; discussion 404-5 [9523523.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 5):40-6 [9609107.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1058-60 [9717995.001]
  • [Cites] J Am Coll Surg. 1998 Dec;187(6):620-5 [9849736.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] J Am Coll Surg. 1999 Sep;189(3):291-9 [10472930.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] N Engl J Med. 2005 Feb 17;352(7):734-5 [15716576.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):425-9 [15677624.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jun;16(6):779-90 [15947041.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):913-9 [15966231.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):900-9 [16184442.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9243-9 [16230673.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):1-7 [16371728.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):240-8 [16455457.001]
  • [Cites] Cancer Control. 2006 Jan;13(1):32-41 [16508624.001]
  • [Cites] World J Gastroenterol. 2006 Feb 14;12(6):935-9 [16521223.001]
  • [Cites] Ann Surg Oncol. 2006 May;13(5):651-8 [16538411.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):412-25 [16690429.001]
  • [Cites] Arch Surg. 2006 May;141(5):460-6; discussion 466-7 [16702517.001]
  • [Cites] Am Surg. 2006 May;72(5):391-2 [16719190.001]
  • [Cites] Arch Surg. 2006 Jun;141(6):581-7; discussion 587-8 [16785359.001]
  • [Cites] Surg Clin North Am. 2006 Aug;86(4):1005-22 [16905421.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):696-703 [16916386.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10):1261-8 [16947009.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4983-90 [17075116.001]
  • [Cites] Eur J Surg Oncol. 2007 Feb;33(1):67-71 [17174059.001]
  • [Cites] Br J Surg. 2007 Mar;94(3):274-86 [17315288.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1151-60 [17195913.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1099-106 [17369573.001]
  • [Cites] J Vasc Interv Radiol. 2007 Apr;18(4):553-61; quiz 562 [17446547.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Jul;16(3):525-36, viii [17606192.001]
  • [Cites] Arch Surg. 2007 Jul;142(7):675-82 [17638807.001]
  • [Cites] Zentralbl Chir. 2007 Aug;132(4):293-9 [17724630.001]
  • (PMID = 19788748.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 97
  • [Other-IDs] NLM/ PMC2763868
  •  go-up   go-down


8. Mahmoud N, Bullard Dunn K: Metastasectomy for stage IV colorectal cancer. Dis Colon Rectum; 2010 Jul;53(7):1080-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasectomy for stage IV colorectal cancer.
  • Metastatic colorectal cancer traditionally has been considered incurable.
  • In this article, we review the history and current status of metastasectomy in stage IV colorectal cancer.
  • [MeSH-major] Brain Neoplasms / surgery. Colorectal Neoplasms. Hepatectomy / methods. Liver Neoplasms / surgery. Lung Neoplasms / surgery. Ovarian Neoplasms / surgery. Pneumonectomy / methods


9. Ide Y, Murata K: [Laparoscopic bowel resection for stage IV colorectal cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2582-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic bowel resection for stage IV colorectal cancer].
  • The purpose of this study was to review the outcomes of laparoscopic bowel resection for patients with Stage IV colorectal cancer.
  • Twenty nine patients with cStage IV disease were undergone a bowel resection during the period from April 2006 to December 2009 in our hospital.
  • Hence, a laparoscopic bowel resection is safe and feasible option for Stage IV colorectal cancer patients.
  • [MeSH-major] Colorectal Neoplasms / surgery. Laparoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224646.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Fukunaga Y, Higashino M, Tanimura S, Takemura M, Fujiwara Y, Osugi H: Laparoscopic surgery for stage IV colorectal cancer. Surg Endosc; 2010 Jun;24(6):1353-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for stage IV colorectal cancer.
  • BACKGROUND: The role of laparoscopic surgery in the management of stage IV colorectal cancer remains uncertain.
  • METHODS: Sixty-five patients with stage IV disease from among 578 colorectal cancer patients who underwent laparoscopic surgery since 2001 were compared with 513 patients who had stage 0-III disease.
  • The criteria for excluding stage IV patients from laparoscopic surgery were huge tumors, low rectal cancer, massive ascites due to peritoneal seeding, bowel perforation and/or obstruction, and poor general condition and/or cachexia.
  • The open conversion rate was 4.6% (3/65 patients) in the stage IV group and 2.7% (14/513 patients) in the stage 0-III group, and the difference between the groups was not significant.
  • In the stage IV group, depth of tumor invasion and tumor diameter were both significantly greater than in the stage 0-III group.
  • However, operating time and blood loss were similar in the two groups (stage IV: 189.0 min and 95.0 g; stage 0-III: 182.5 min and 60.0 g), although blood loss was significantly greater in the stage IV group when patients undergoing rectal surgery were compared.
  • CONCLUSIONS: Despite their larger and more invasive tumors, the short-term outcome of laparoscopic surgery in patients with stage IV colorectal cancer was similar to that for stage 0-III patients.
  • This result indicates that laparoscopic surgery can be successfully performed in selected stage IV colorectal cancer patients.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 May;25(5):1706-7 [21057962.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S53-8 [8831547.001]
  • [Cites] Surg Endosc. 1995 Jul;9(7):811-6 [7482191.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2013-9 [18421054.001]
  • [Cites] Surg Today. 1996;26(11):882-9 [8931218.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Surg Endosc. 2008 Jun;22(6):1452-8 [17972132.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Ann Surg. 1999 Apr;229(4):487-92 [10203080.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):321-8 [11790211.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):43-6 [15529197.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):869-77 [15855226.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):518-21 [12925093.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Dis Colon Rectum. 2006 Feb;49(2):213-8 [16416080.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2007 Apr;17(2):79-82 [17450084.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Am Coll Surg. 2002 Apr;194(4):509-37 [11949756.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7074-9 [18981005.001]
  • (PMID = 20033715.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Moloo H, Bédard EL, Poulin EC, Mamazza J, Grégoire R, Schlachta CM: Palliative laparoscopic resections for Stage IV colorectal cancer. Dis Colon Rectum; 2006 Feb;49(2):213-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative laparoscopic resections for Stage IV colorectal cancer.
  • PURPOSE: Issues surrounding the safety and efficacy of palliative laparoscopic resections for patients with Stage IV colorectal cancer have not been explicitly examined in the literature.
  • This article describes our experience with laparoscopic procedures for patients with Stage IV colorectal cancer and compares their perioperative outcomes to a contemporaneous group of patients with clinically curable (Stages I-III) disease.
  • METHODS: A prospective database of laparoscopic resections for colorectal cancer performed between 1991 and 2002 was reviewed.
  • Patients with Stage IV disease had larger tumors (5.4+/-2.3 cm vs. 4.6+/-2.6 cm, P=0.04) which contributed to an increased rate of conversion (22 percent vs. 11 percent, P=0.05) with most conversions secondary to tumor fixation or bulk (64 percent) preventing determination of resectability.
  • CONCLUSIONS: A palliative laparoscopic resection is a safe and feasible option and presents acceptable morbidity and mortality in patients with Stage IV colorectal cancer.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Palliative Care

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16416080.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Konyalian VR, Rosing DK, Haukoos JS, Dixon MR, Sinow R, Bhaheetharan S, Stamos MJ, Kumar RR: The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis; 2007 Jun;9(5):430-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of primary tumour resection in patients with stage IV colorectal cancer.
  • OBJECTIVE: The management of stage IV colorectal cancer is controversial.
  • The purpose of this study was to determine the role of resection of the primary tumour in patients with stage IV colorectal cancer, with specific attention paid to survival benefit and safety.
  • METHOD: This was a retrospective review of all stage IV colon and rectal cancer patients in our tumour registry between 1991 and 2002.
  • CONCLUSION: Palliative resection of the primary tumour plays an essential role in the management of stage IV colorectal cancer.
  • [MeSH-major] Colectomy / adverse effects. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504340.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Osawa G, Yoshimatsu K, Yokomizo H, Umehara A, Fujimoto T, Watanabe K, Otani T, Matsumoto A, Itagaki H, Ogawa K: [A prediction of prognosis by A-L score in patients with stage IV colorectal cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2256-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A prediction of prognosis by A-L score in patients with stage IV colorectal cancer].
  • We analyzed the relationship between A-L score classified by serum albumin level and lymphocytes/white blood cells ratio and clinicopathological features in patients with Stage IV colorectal cancer.
  • In the multivariate analysis, the A-L score was independent prognostic factor in Stage IV colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106588.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Hotokezaka M, Jimi S, Hidaka H, Ikeda T, Uchiyama S, Nakashima S, Tsuchiya K, Chijiiwa K: Factors influencing outcome after surgery for stage IV colorectal cancer. Surg Today; 2008;38(9):784-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing outcome after surgery for stage IV colorectal cancer.
  • PURPOSE: According to the classification system of the Japanese Society for Cancer of the Colon and Rectum, Stage IV colorectal cancer is characterized by distant metastasis, which is defined by four factors: liver metastasis (H factor), metastasis to organs other than the liver (M factor), peritoneal dissemination (P factor), and distant lymph node metastasis (N factor).
  • We conducted this study to investigate the postsurgical prognosis of patients with Stage IV colorectal cancer (CRC), in reference to each of these four factors.
  • METHODS: We analyzed the medical records of 73 patients who underwent surgery for Stage IV CRC at our hospital between 1991 and 2001.
  • RESULTS: Univariate analysis revealed that P0 or P1 CRC (P < 0.001), absence of the M factor (P = 0.024), well or moderately differentiated adenocarcinoma (P < 0.001), resection of the primary tumor (P < 0.001), and curability B surgery (P < 0.0001) were associated with a better prognosis than other types of Stage IV CRC.
  • Multivariate analysis revealed that tumor differentiation and surgical curability affected cancer-specific survival significantly.
  • CONCLUSION: Surgery with curative intent should be considered for patients with Stage IV CRC defined by the P1 factor or H factor.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Colorectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Surg. 2005;22(6):401-14 [16479107.001]
  • [Cites] Br J Surg. 1990 Nov;77(11):1241-6 [2253003.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):393-8 [8625119.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):313-27 [10473851.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Ann Thorac Surg. 2006 Jul;82(1):254-60 [16798225.001]
  • [Cites] Br J Surg. 1993 Aug;80(8):1032-5 [8402060.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S15-25 [10357554.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Tech Coloproctol. 2005 Jul;9(2):95-103 [16007367.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):809-14 [10854549.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):499-506 [12507085.001]
  • [Cites] Dis Colon Rectum. 1988 Oct;31(10):786-92 [3168665.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):732-9 [14502146.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):1066-71 [15286972.001]
  • (PMID = 18751942.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Melmed G, Becerra C, Saracino G, Bowman E, McCollum AD: Chemotherapy-free interval following initial chemotherapy in patients with stage IV colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15096

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-free interval following initial chemotherapy in patients with stage IV colorectal cancer.
  • : e15096 Background: Patients with metastatic colorectal cancer (mCRC) have improved survival due to recent advances in systemic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964611.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK: Erratum to: The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status. Int J Colorectal Dis; 2007 Dec;22(12):1559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erratum to: The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumFor] Int J Colorectal Dis. 2007 Nov;22(11):1301-10 [17486358.001]
  • (PMID = 28980013.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Published Erratum
  • [Publication-country] Germany
  •  go-up   go-down


17. Takemoto H, Tomita N, Murata K, Fukunaga M, Okamura S, Ohue M, Ishida H, Tanimoto K, Hiyama K, Nishiyama M: Optimal patient selection for CPT-11 chemotherapy in colorectal cancer: Quantitative prediction of tumor response and overall survival using expression data of novel marker genes. J Clin Oncol; 2009 May 20;27(15_suppl):e14529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal patient selection for CPT-11 chemotherapy in colorectal cancer: Quantitative prediction of tumor response and overall survival using expression data of novel marker genes.
  • CPT-11 was intravenously administered on Days 1, 8, and 15, every 4 weeks in chemo-naive patients with stage IV colorectal cancer after palliative operation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Blitzer JB, Shbeeb I, Neoman A, Azaren K, Paulsen M, Evans S, Nagourney R: Functional profiling in stage IV colorectal cancer: A phase II trial of individualized therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional profiling in stage IV colorectal cancer: A phase II trial of individualized therapy.
  • : e15124 Background: The introduction of new classes of agents has improved survival in colorectal cancer (CRC) yet the accurate selection of candidates for these often costly & toxic drugs remains a challenge.
  • METHODS: To address the complexity and redundancy of cell-death signaling pathways, we applied Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) (Nagourney, R.
  • 1<sup>st</sup> line EVBR were FOLFOX 3/12 (25%); FOLFIRI 2/12 (16%); FOLFOX/Erbitux 2/12(16%); FOLFOX/Avastin 1/12 (8%); FOLFOX/Avastin/Erbitux 1/12(8%); Irinotecan/Avastin/Erbitux 2/12(16%); IROX/Avastin 1/12(8%).
  • CONCLUSIONS: EVA/PCD ORR in Stage IV CRC of 66%, many durable, compares favorably with reports in this population.
  • EVA/PCD analysis warrants further evaluation in CRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Vieitez J, Jiménez Fonseca P, Fernandez de Sanmamed M, Pitiot AS, Crespo G, Berros J, Muriel C, Izquierdo M, Pardo P, Lacave A: Incidence and significance of K-RAS mutation in first line treatment of colorectal cancer (cc): Experience of a single institution (Hospital Universitario Central de Asturias (HUCA)). J Clin Oncol; 2009 May 20;27(15_suppl):e15081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and significance of K-RAS mutation in first line treatment of colorectal cancer (cc): Experience of a single institution (Hospital Universitario Central de Asturias (HUCA)).
  • METHODS: Sample tissue of alive patients diagnosed of stage IV colorectal cancer were analyzed for the presence of K-RAS mutation by PCR amplification and direct sequencing.
  • RESULTS: From IV to XII 08 122 paraffin embedded samples were analyzed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. de Gramont Lesparre AH, Chibaudel B, Bourges O, Perez-Staub N, Tournigand C, Maindrault-Goebel F, André T, Larsen AK, Afchain P, Louvet C: Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol; 2009 May 20;27(15_suppl):4024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy.
  • : 4024 Background: Oxaliplatin combined with fluoropyrimidines is standard adjuvant therapy in stage III colon cancer and first-line therapy in stage IV colorectal cancer.
  • METHODS: Stage IV pts entered in the OPTIMOX1 and 2 studies (FOLFOX4, FOLFOX7 followed by maintenance without oxaliplatin or chemotherapy holidays) and pts having relapsed after metastases surgery and neoadjuvant or adjuvant FOLFOX for resectable stage IV were eligible if they were rechallenged with FOLFOX.
  • RESULTS: 330 pts were included: male 60%, colon/rectum/both 62%/35%/2%, resectable/unresectable: 14%/86%, PS 0-1 / >1: 90%/10%, sites 1/>1: 57%/43%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961524.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong W, Paty PB: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol; 2009 May 20;27(15_suppl):CRA4030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961295.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Fuchs C, Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Bertagnolli MM: KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol; 2009 May 20;27(15_suppl):4037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803.
  • : 4037 Purpose: KRAS mutation in stage IV colorectal cancer predicts resistance to anti-EGFR targeted treatment (cetuximab or panitumumab).
  • However, whether the presence of KRAS mutation independently predicts the survival of colon cancer patients remains uncertain.
  • METHODS: We conducted a prospective observational study of 508 cases identified among 1264 patients with stage III colon cancer who enrolled in a randomized adjuvant chemotherapy trial (5-fluorouracil, leucovorin with or without irinotecan) between April 1999 and May 2001 (CALGB 89803; Saltz et al.
  • Kaplan-Meier and Cox proportional hazard models were used to assess the significance of KRAS mutational status and adjusted for potential confounders including age, sex, tumor location, T stage, N stage, performance status, adjuvant chemotherapy arm and microsatellite instability (MSI) status.
  • CONCLUSIONS: In this large clinical trial of chemotherapy in patients with stage III colon cancer, KRAS mutational status was not associated with any significant influence on disease-free or overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961543.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zafar Y, Grambow SC, Abbott DH, Malin JL, Zullig LL, Kolimaga JT, Provenzale DT, CanCORS Steering Committee: Factors associated with chemotherapy receipt and intensity for stage IV colorectal cancer (CRC): A multihealth system, population-based study. J Clin Oncol; 2009 May 20;27(15_suppl):6519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with chemotherapy receipt and intensity for stage IV colorectal cancer (CRC): A multihealth system, population-based study.
  • : 6519 Background: Little is known about chemotherapy practice patterns for patients with stage IV CRC.
  • METHODS: Cancer Outcomes Research & Surveillance Consortium (CanCORS) is a prospective cohort study including patients with incident CRC sampled from a set of defined populations and health systems.
  • Eligible patients for this analysis (n = 742) had stage IV CRC and abstracted medical record data, including stage, chemotherapy, comorbidity (measured by the Adult Comorbidity Evaluation 27 index), and sociodemographic data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964025.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sakamoto Y, Fujita S, Akasu T, Nara S, Esaki M, Shimada K, Yamamoto S, Moriya Y, Kosuge T: Is surgical resection justified for stage IV colorectal cancer patients having bilobar hepatic metastases?--an analysis of survival of 77 patients undergoing hepatectomy. J Surg Oncol; 2010 Dec 1;102(7):784-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is surgical resection justified for stage IV colorectal cancer patients having bilobar hepatic metastases?--an analysis of survival of 77 patients undergoing hepatectomy.
  • BACKGROUND: Surgical indication for stage IV colorectal cancer patients with bilobar hepatic metastases may be controversial.
  • METHODS: Retrospective cohort analysis was performed using data of 200 patients who underwent surgical resections for synchronous metastases of colorectal cancer between 1990 and 2005.
  • The survival of 11 T4 cancer patients with six or more metastases was poor, but significantly better than that of 95 patients with unresectable bilobar metastases (P = 0.04).
  • CONCLUSION: Surgical resection in stage IV colorectal cancer patients having bilobar hepatic metastases was justified in the present setting.
  • [MeSH-major] Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Hepatectomy. Liver Neoplasms / mortality. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20872814.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Stillwell AP, Buettner PG, Ho YH: Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg; 2010 Apr;34(4):797-807
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone.
  • BACKGROUND There is no consensus regarding the appropriate management of asymptomatic and minimally symptomatic patients with stage IV colorectal cancer and irresectable metastases.
  • CONCLUSIONS To date, only retrospective data are available, showing that palliative resection of the primary tumor in asymptomatic or minimally symptomatic patients with stage IV colorectal cancer is associated with longer survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery


26. Hasegawa S, Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tajima T, Nakasaki H, Makuuchi H: Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination. Oncol Rep; 2006 May;15(5):1185-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
  • Among 125 patients with peritoneal dissemination (P1-3) of colorectal cancer, including those with other synchronous metastases, the 5-year overall survival (OS) rate was 13.3% for P1 patients (n=30), 12.8% for P2 patients (n=39), and 1.8% for P3 patients (n=56) (P1 vs. P2, p=N.S.
  • These results suggest that the prognosis of stage IV colorectal cancer with P3 peritoneal dissemination is extremely poor.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / mortality. Fluorouracil / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / mortality

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596184.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Cook AD, Single R, McCahill LE: Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. Ann Surg Oncol; 2005 Aug;12(8):637-45
Genetic Alliance. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000.
  • BACKGROUND: Surgical resection of the primary tumor for patients who present with incurable stage IV colorectal cancer is controversial.
  • We evaluated the use of primary tumor resection in patients presenting with stage IV colorectal cancer.
  • METHODS: Patients with stage IV colorectal cancer diagnosed between 1988 and 2000 were selected from the Surveillance, Epidemiology, and End Results database.
  • RESULTS: A total of 17,658 (66%) of the 26,754 patients presenting with stage IV colorectal cancer underwent primary tumor resection.
  • Patients with resected disease were more likely to be young (mean age of 67.1 vs. 70.3 years) and to have right-sided tumors (75.3%, 73.0%, and 45.6%, respectively, for right, left, and rectal; P < .001).
  • In all age groups, patients undergoing resection had higher median and 1-year survival rates (colon: 11 vs. 2 months, 45% vs. 12%, P < .001; rectum: 16 vs. 6 months, 59% vs. 25%, P < .001) when compared with patients who did not undergo resection.
  • CONCLUSIONS: Most patients who present with stage IV colorectal cancer undergo resection of the primary tumor.
  • Further investigation of the role of surgery in the management of incurable stage IV colorectal cancer is warranted.
  • [MeSH-major] Colectomy / statistics & numerical data. Colonic Neoplasms / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Aug;12(8):581-2 [15959678.001]
  • (PMID = 15965730.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK: The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status. Int J Colorectal Dis; 2007 Nov;22(11):1301-10
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status.
  • BACKGROUND AND AIMS: Approximately 20% of patients with colorectal cancer are initially diagnosed with stage IV.
  • RESULTS: For the curative operation group, the 5-year survival rate was 34.5%, and the prognostic factors of survival and recurrence were male gender (p = 0.003, 0.009), pathologic N stage (p < 0.001, p = 0.002), and perineural invasion (p = 0.003, p = 0.026), respectively.
  • CONCLUSIONS: The potential predictors of survival for curative stage IV colorectal cancer were male gender, pathologic N stage, and perineural invasion.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Health Status

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Colorectal Dis. 2007 Dec;22(12):1559. Lee, One Suk [corrected to Lee, Won Suk]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1092-8 [11488795.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] Eur J Surg Oncol. 2001 Jun;27(4):364-7 [11417981.001]
  • [Cites] Dis Colon Rectum. 2000 Jan;43(1):83-91 [10813129.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Jul;30(7):1009-11 [12894720.001]
  • [Cites] Chest Surg Clin N Am. 1998 Feb;8(1):119-26 [9515176.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):2-23 [12780921.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Cancer. 1979 Mar;43(3):961-8 [427737.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] JAMA. 1982 May 28;247(20):2809-10 [7077785.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1397-400 [7489177.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):904-11 [1588370.001]
  • [Cites] Pathol Res Pract. 1986 Jun;181(3):296-300 [3748876.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] J Am Coll Surg. 2006 Mar;202(3):468-75 [16500252.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):732-9 [14502146.001]
  • [Cites] Lancet. 1995 Jul 8;346(8967):68 [7603214.001]
  • [Cites] BMJ. 1993 Mar 20;306(6880):752-5 [7683942.001]
  • [Cites] Rev Med Interne. 2004 Feb;25(2):124-8 [14744642.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):698-702 [4041728.001]
  • [ErratumIn] Int J Colorectal Dis. 2007 Dec;22(12 ):1559 [28980013.001]
  • (PMID = 17486358.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Kato T, Miyake Y, Oshima K, Handa R, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A clinical significance of direct invasion to adjacent organs in stage IV colorectal cancer]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1827-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical significance of direct invasion to adjacent organs in stage IV colorectal cancer].
  • We studied a clinical significance of direct invasion to adjacent organs in Stage IV colorectal cancer.
  • The subjects were 19 consecutive patients who underwent R0 surgery to the primary tumor for colorectal carcinoma, pT4, M1 1995-2003.
  • [MeSH-major] Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212119.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Mukai M, Oida Y, Tajima T, Kishima K, Ninomiya H, Sato S, Nakamura M, Nakasaki H, Makuuchi H: Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncol Rep; 2006 Oct;16(4):865-70
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis.
  • Among 41 patients with synchronous liver metastases of colorectal cancer, 15 patients underwent synchronous resection of their liver metastases and achieved a median survival time (MST) of 1,441 days (versus 748 days for the 26 patients without resection, p=0.038), a median relapse-free survival time of 652 days (MST not reached), and a recurrence rate in the residual liver of 20% (3/15 patients).
  • These results suggest that the present alternating therapy may become a standard regimen for patients in whom synchronous resection of liver metastases is impossible and patients who have stage IV colorectal cancer with a risk of recurrence in the remnant liver and/or at extrahepatic sites such as the lungs.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969507.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Gervaz P, Rubbia-Brandt L, Andres A, Majno P, Roth A, Morel P, Mentha G: Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol; 2010 Oct;17(10):2714-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
  • BACKGROUND: We report the histopathological results of a novel "inversed" strategy designed to manage patients with colorectal cancer (CRC) who have synchronous liver metastases by using chemotherapy first, liver surgery second, and resection of the primary tumor as a final step.
  • METHODS: Twenty-nine patients with stage IV CRC received a combination of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (OCFL) for 3-4 months.
  • Primary tumor location was right colon (n = 5), left colon (n = 7), and rectum (n = 17 patients).
  • CONCLUSIONS: In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lymph Nodes / drug effects. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405223.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Karoui M, Soprani A, Charachon A, Delbaldo C, Vigano L, Luciani A, Cherqui D: Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. Eur J Surg Oncol; 2010 Jan;36(1):58-64
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer.
  • AIM: Management of patients with irresectable stage IV colorectal cancer is controversial.
  • PATIENTS AND METHODS: From 2000 to 2007, 68 of 115 consecutive patients admitted with stage IV colorectal cancer were considered irresectable.
  • CONCLUSION: In unselected patients with irresectable stage IV colorectal cancer, primary chemotherapy with or without stent is feasible in more than 50% of cases and is associated with a low rate of secondary surgery for complicated primary tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Stents

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19926243.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Scabini S, Rimini E, Romairone E, Scordamaglia R, Pertile D, Ferrando V: Factors predicting survival in surgical palliative resection of stage IV colorectal cancer. Minerva Chir; 2009 Jun;64(3):303-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting survival in surgical palliative resection of stage IV colorectal cancer.
  • AIM: Colorectal cancer (CRC) harbors accumulated genetic alterations with cancer progression, which results in uncontrollable disease.
  • To regulate the most malignant CRC, we have to know the most dismal phenotype of stage IV disease.
  • METHODS: A retrospective review of our Oncological Surgical Unit was performed (from 2005 to 2008) to extract the 52 resected stage IV CRC.
  • RESULTS: In stage IV CRC with noncurable resection, the most robust univariate predictors for poor prognosis were preoperative high value of CEA.
  • CONCLUSIONS: Our results suggested that only preoperative value CEA is associated with poor prognosis in stage IV CRC.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Palliative Care / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536056.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


34. Katoh H, Yamashita K, Kokuba Y, Satoh T, Ozawa H, Hatate K, Ihara A, Nakamura T, Onosato W, Watanabe M: Surgical resection of stage IV colorectal cancer and prognosis. World J Surg; 2008 Jun;32(6):1130-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of stage IV colorectal cancer and prognosis.
  • BACKGROUND: Colorectal cancer (CRC) harbors accumulated genetic alterations with cancer progression, which results in uncontrollable disease.
  • To regulate the most malignant CRC, we have to know the most dismal phenotype of stage IV disease.
  • METHODS: A retrospective review of the Kitasato University Hospital was performed (from 1990 to 2001) to extract the 162 resected stage IV CRC.
  • RESULTS: In stage IV CRC with noncurable resection, the most robust univariate predictors for poor prognosis were preoperative high value of CA19-9, peritoneal dissemination, depth of invasion, age, extent of liver metastases, pathologic lymph node metastasis status, and gender as tumor factors, and postoperative therapy, perioperative transfusion, and lymph node dissection extent as treatment factors.
  • [MeSH-major] Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jul;228(1):59-63 [9671067.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Arch Biochem Biophys. 2004 Jun 15;426(2):122-31 [15158662.001]
  • [Cites] Cancer Lett. 2007 Jan 8;245(1-2):149-55 [16488536.001]
  • [Cites] Hepatogastroenterology. 2002 Jan-Feb;49(43):160-4 [11941943.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2B):1377-83 [16619547.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):725-8 [10952775.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):181-7 [12668282.001]
  • [Cites] Med Hypotheses. 2001 Sep;57(3):337-43 [11516226.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):6-11 [16368485.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Sci. 2004 May;95(5):377-84 [15132763.001]
  • [Cites] J Surg Oncol. 2000 Nov;75(3):165-71 [11088047.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3409-18 [16585162.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):485-95 [12498717.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6127-32 [16144911.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):962-6 [12963652.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):580-5 [15103491.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Cancer Metastasis Rev. 1992 Nov;11(3-4):325-51 [1423821.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):161-7 [11870500.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1251-5 [15865074.001]
  • [Cites] Lancet. 1995 Jul 8;346(8967):115 [7603185.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Nat Med. 2004 Aug;10 (8):789-99 [15286780.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4597-603 [14673048.001]
  • (PMID = 18340483.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


35. Armbrust T, Sobotta M, Füzesi L, Grabbe E, Ramadori G: Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases. Eur J Gastroenterol Hepatol; 2007 Nov;19(11):988-94
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
  • BACKGROUND: Although modern chemotherapy of stage IV advanced colorectal cancer (CRC) has impressively improved overall survival, the response of the primary tumor has not been studied because surgical resection of the primary continues to be the standard procedure in stage IV CRC.
  • AIM: Long-term follow-up of the primary in patients with stage IV CRC under chemotherapy.
  • METHODS AND RESULTS: Here we report on the histological changes in the primary tumor in four patients suffering from stage IV CRC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adenoma / drug therapy. Adenoma / pathology. Aged. Colon / pathology. Colonic Polyps / drug therapy. Colonic Polyps / pathology. Colonic Polyps / surgery. Colonoscopy. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049169.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Scabini S, Rimini E, Romairone E, Scordamaglia R, Pertile D, Ferrando V: Survival in surgical palliative resection of stage IV colorectal cancer: short term results in a single institution. Minerva Chir; 2010 Feb;65(1):17-20
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in surgical palliative resection of stage IV colorectal cancer: short term results in a single institution.
  • AIM: In this study, we analyze clinical parameters, survival and possible advantage of surgery in patients affected by symptomatic Dukes D colorectal cancer.
  • METHODS: From July 2005 to December 2008 at our Oncological Surgery Unit we treated 69 symptomatic stage IV CRC, 46 of them resected at our Oncological Surgical Unit.
  • RESULTS: In symptomatic stage IV CRC with non-curable resection, the most robust univariate predictor for poor prognosis was impossibility to cancer resection.
  • CONCLUSION: Our results suggested that impossibility to perform cancer resection is associated with poor prognosis in symptomatic stage IV CRC and worse survival also in the short term.
  • [MeSH-major] Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Palliative Care

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212413.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


37. Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut A, Dziki A: Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? Colorectal Dis; 2010 Jul;12(7 Online):e61-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients?
  • OBJECTIVE: The aims of the study were to analyse the early and late results of surgical treatment in patients with stage IV colorectal cancer (CRC) and to evaluate the effect of primary tumour resection and other clinical factors on survival.
  • METHOD: A group of 134 patients with stage IV CRC was electively operated on between 1996 and 2000.
  • CONCLUSION: Primary tumour resection in stage IV CRC increases the risk of postoperative complications.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Neoplasm Staging. Palliative Care / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486103.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ: Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol; 2008 Nov;19(11):1829-35
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases.
  • BACKGROUND: In patients with asymptomatic colorectal cancer with irresectable metastatic disease, the optimal treatment strategy remains controversial.
  • PATIENTS AND METHODS: Seven studies reported series of patients with asymptomatic stage IV colorectal cancer and compared first-line chemotherapy with surgery for the primary tumor (n = 850 patients).
  • CONCLUSIONS: For patients with stage IV colorectal cancer, resection of the asymptomatic primary tumor provides only minimal palliative benefit, can give rise to major morbidity and mortality and therefore potentially delays beneficial systemic chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662955.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


39. Law WL, Fan JK, Poon JT, Choi H, Lo OS: Laparoscopic bowel resection in the setting of metastatic colorectal cancer. Ann Surg Oncol; 2008 May;15(5):1424-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic bowel resection in the setting of metastatic colorectal cancer.
  • BACKGROUND: This study aimed to review the outcomes of laparoscopic colorectal resection for patients with stage IV colorectal cancer.
  • METHODS: From the prospectively collected database for patients who underwent surgery for colorectal cancer in our institution, those with stage IV colorectal cancer who underwent elective resection of tumor during the period from January 2000 to June 2006 were included.
  • CONCLUSIONS: Colorectal resection can be performed safely in patients with stage IV colorectal cancer.
  • [MeSH-major] Bone Neoplasms / surgery. Colorectal Neoplasms / surgery. Laparoscopy. Liver Neoplasms / surgery. Lung Neoplasms / surgery. Peritoneal Neoplasms / surgery


40. Baumhoer D, Armbrust T, Ramadori G: Nonsurgical treatment of the primary tumor in four consecutive cases of metastasized colorectal carcinoma. Endoscopy; 2005 Dec;37(12):1232-6
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical treatment of the primary tumor in four consecutive cases of metastasized colorectal carcinoma.
  • BACKGROUND AND STUDY AIMS: Surgical resection of the primary tumor is standard treatment in stage IV colorectal cancer, but palliative surgery is associated with high morbidity and mortality and with uncertain benefit.
  • By studying a small series of such patients, we aimed to assess whether endoscopic techniques can offer an effective alternative form of nonsurgical palliative treatment for the prevention of local complications caused by a primary colorectal tumor.
  • PATIENTS AND METHODS: We treated four consecutive patients who had stage IV colorectal cancer by endoscopic tumor debulking, either using a standard polypectomy snare technique alone or by argon plasma coagulation ablation followed by snare debulking of the primary tumor.
  • CONCLUSIONS: We believe that surgical resection of the primary tumor is not appropriate in all patients with stage IV colorectal cancer, and that this form of treatment should be reserved for patients with signs of complete obstruction in whom local ablative procedures are not possible.
  • Simple endoscopic techniques for treatment of the primary tumor, in conjunction with systemic chemotherapy, may be the most suitable form of management for patients with stage IV colorectal tumors.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Colonoscopy / methods. Colorectal Neoplasms / therapy. Intestinal Obstruction / therapy. Liver Neoplasms / secondary. Palliative Care / methods


41. Schwartz RN: Management of early and advanced colorectal cancer: therapeutic issues. Am J Health Syst Pharm; 2008 Jun 1;65(11 Suppl 4):S8-14; quiz S22-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of early and advanced colorectal cancer: therapeutic issues.
  • PURPOSE: The staging of colorectal cancer, therapeutic decision making in the management of early and advanced colorectal cancer, and dilemmas posed by drug-related toxicity are discussed.
  • SUMMARY: Staging of colorectal cancer occurs after surgery and is based on the extent of disease invasiveness and dissemination.
  • Surgery is the primary treatment for stage I disease.
  • Adjuvant chemotherapy is recommended after resection in selected high-risk patients with stage II disease and in all patients with stage III disease.
  • Treatment of stage IV colorectal cancer is based on the type of prior therapy and patient-specific factors.
  • Bevacizumab in combination with chemotherapy is first-line therapy for stage IV disease.
  • Age alone should not preclude the use of chemotherapy in stage IV colorectal cancer, although the ability to tolerate drug-related toxicity may be a consideration.
  • The optimal duration of chemotherapy in patients with early and metastatic colorectal cancer is unclear.
  • CONCLUSION: The optimal approach to the treatment of colorectal cancer depends on several considerations, including patient-specific factors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499889.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


42. Handa R, Kato T, Miyake Y, Oshima K, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1795-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
  • We report a long-term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • An advanced colon cancer of the cecum was found with a colonoscopy.
  • Abdominal CT showed advanced colon cancer with adjacent organ involvement and multiple liver metastases.
  • He received right hemi-colon resection and right hepatic lobectomy.
  • Usually the prognoses of Stage IV colorectal cancer patients are very unpleasant.
  • Even thougn a few patients with Stage IV colorectal cancer can be a long-term survivor after multiple operations, we need to consider carefully the indication of the operation and QOL for a Stage IV colorectal cancer patient.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Seo GJ, Park JW, Yoo SB, Kim SY, Choi HS, Chang HJ, Shin A, Jeong SY, Kim DY, Oh JH: Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol; 2010 Jul 1;102(1):94-9
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer.
  • BACKGROUND: The initial surgical management of asymptomatic patients with unresectable stage IV colorectal cancer (CRC) is still controversy.
  • The aim of this study was to compare the incidence of major intestinal complications in asymptomatic patients who received palliative treatment for unresectable stage IV CRC, according to the type of treatment.
  • CONCLUSIONS: In asymptomatic patients with unresectable stage IV CRC, first-line chemotherapy may be considered safe, with no increased risk of major intestinal complications compared with primary tumor resection plus chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Intestinal Diseases / etiology. Palliative Care. Postoperative Complications

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20578086.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB: Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol; 2009 Jul 10;27(20):3379-84
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
  • PURPOSE: The purpose of this study was to describe the frequency of interventions necessary to palliate the intact primary tumor in patients who present with synchronous, stage IV colorectal cancer (CRC) and who receive up-front modern combination chemotherapy without prophylactic surgery.
  • Of those 213 patients, 47 patients (20%) ultimately underwent elective colon resection at the time of metastasectomy, and eight patients (3%) underwent this resection during laparotomy for hepatic artery infusion pump placement.
  • CONCLUSION: Most patients with synchronous, stage IV CRC who receive up-front modern combination chemotherapy never require palliative surgery for their intact primary tumor.
  • These data support the use of chemotherapy, without routine prophylactic resection, as the appropriate standard practice for patients with neither obstructed nor hemorrhaging primary colorectal tumors in the setting of metastatic disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Palliative Care / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Br J Surg. 2001 Oct;88(10):1352-6 [11578291.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Gastroenterol Clin Biol. 2004 May;28(5):434-7 [15243315.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3475-84 [15337795.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3706-12 [15867200.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):140-1 [16408142.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):137-9 [16418888.001]
  • [Cites] Eur J Cancer. 1999 Sep;35(9):1338-42 [10658524.001]
  • (PMID = 19487380.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3646319
  •  go-up   go-down


45. Huang L, Pickle LW, Stinchcomb D, Feuer EJ: Detection of spatial clusters: application to cancer survival as a continuous outcome. Epidemiology; 2007 Jan;18(1):73-87
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of spatial clusters: application to cancer survival as a continuous outcome.
  • We use this approach to study the spatial patterns of survival of patients with stage III or stage IV colorectal cancer or with stage I/II, stage III, or stage IV lung cancer in the State of California and the County of Los Angeles (LA) diagnosed during 1988 through 2002.
  • [MeSH-major] Cluster Analysis. Colorectal Neoplasms / mortality. Logistic Models. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179759.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Trabal J, Leyes P, Forga M, Maurel J: Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr Hosp; 2010 Sep-Oct;25(5):736-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition.
  • OBJECTIVES: To assess the effect of an intervention with an Eicosapentaenoic Acid-enriched oral nutritional supplement on chemotherapy tolerability in patients with advanced colorectal cancer.
  • METHODS: Thirteen patients diagnosed with stage IV colorectal cancer were included.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Colorectal Neoplasms / complications. Dietary Supplements. Eicosapentaenoic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21336429.001).
  • [ISSN] 1699-5198
  • [Journal-full-title] Nutrición hospitalaria
  • [ISO-abbreviation] Nutr Hosp
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


47. Pasetto LM, Falci C, Rizzo E, De Salvo GL, Gasparini G, D'Andrea M, Bajetta E, Platania M, Alabiso O, Miraglia S, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Giordano M, Luchena G, Buzzi F, Ricotta R, Siena S, Monfardini S: Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Res; 2008 May-Jun;28(3B):1813-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units.
  • BACKGROUND: Palliative chemotherapy significantly reduces mortality in patients with stage IV colon cancer, but is less prescribed with rising age.
  • PATIENTS AND METHODS: From January to December 2004, 78 files on the management of stage IV colorectal cancer (CRC) patients over 70 years, collected from 10 Italian Centres, were retrospectively examined.

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630465.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; 1-UFT protocol
  •  go-up   go-down


48. Clements D, Dhruva Rao P, Ramanathan D, Adams R, Maughan TS, Davies MM: Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer. Colorectal Dis; 2009 Oct;11(8):845-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer.
  • OBJECTIVE: The management of the asymptomatic primary in stage IV colorectal cancer presents a dilemma.
  • Our practice in patients with stage IV disease is palliative chemotherapy and symptom control.
  • We reviewed our nonoperatively managed patients with colorectal liver metastases in order to identify the percentage of patients requiring urgent operative interventions for symptoms related to the primary.
  • SUBJECTS/PATIENTS AND METHOD: A retrospective review of all patients treated for stage IV disease at our institution from 2003-2006 was undertaken.
  • There were no similarities between these three patients in terms of age, sex, site or stage of primary, volume of liver metastases, and alkaline phosphatase (ALP) or carcinoembryonic antigen (CEA) levels.
  • CONCLUSION: Of 37 patients initially treated palliatively for stage IV colorectal cancer, 92% required no surgical treatment of their primary.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2010 Mar;12(3):267; author reply 267-8 [20041926.001]
  • (PMID = 19175637.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


49. Sima CS, Panageas KS, Heller G, Schrag D: Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. Appl Health Econ Health Policy; 2010;8(1):37-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To inform assessments of the quality of cancer care, we describe analytical approaches to characterizing trends in diffusion of chemotherapy drugs subsequent to their US FDA approval.
  • We propose a method that employs time-to-event techniques to describe the probability of utilization of a drug within a specified timeframe subsequent to the diagnosis of cancer.
  • The method proposed is illustrated using Surveillance, Epidemiology, and End Results (SEER)-Medicare data applied to two case studies: gemcitabine, approved for stage III/IV pancreatic cancer; and irinotecan, approved as a second-line therapy for stage IV colorectal cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Colorectal Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Diffusion of Innovation. Models, Statistical. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038192.001).
  • [ISSN] 1175-5652
  • [Journal-full-title] Applied health economics and health policy
  • [ISO-abbreviation] Appl Health Econ Health Policy
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA98353
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


50. Berri RN, Abdalla EK: Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep; 2009 May;11(3):200-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curable metastatic colorectal cancer: recommended paradigms.
  • "Cure" for patients with stage IV colorectal cancer remains elusive, but for a growing subset of patients with colorectal liver metastases (CLMs), cure (ie, > 10-year survival without evidence of disease) is achieved in at least 17% of resected patients.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10 ):1261-8 [16947009.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):293-9 [11224615.001]
  • [Cites] Ann Surg. 2008 Jan;247(1):118-24 [18156931.001]
  • [Cites] Surgery. 2000 May;127(5):512-9 [10819059.001]
  • [Cites] J Surg Oncol. 2005 Sep 1;91(3):173-80 [16118771.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3939-45 [16921046.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4575-80 [17925551.001]
  • [Cites] J Gastrointest Surg. 2007 Nov;11(11):1498-504; discussion 1504-5 [17849166.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4983-90 [17075116.001]
  • [Cites] J Am Coll Surg. 2001 Jul;193(1):109-11 [11442247.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):845-53 [15922194.001]
  • [Cites] Ann Surg. 2006 Jan;243(1):1-7 [16371728.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):165-75 [11167863.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] Ann Surg. 2008 Jul;248(1):138-9; author reply 139-40 [18580219.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Liver Transpl. 2005 Dec;11(12):1481-93 [16315293.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5344-51 [18936472.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):480-6 [10749607.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jan;12(1):165-92, xi [12735137.001]
  • [Cites] Ann Surg Oncol. 2006 Oct;13(10):1271-80 [16955381.001]
  • [Cites] Ann Surg. 2004 Apr;239(4):450-8 [15024305.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):675-80; discussion 680-1 [12049538.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1386-94 [17583900.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2065-72 [16648507.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):460-6 [14998849.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):172-7 [16041206.001]
  • [Cites] J Gastrointest Surg. 2006 Jan;10(1):86-94 [16368496.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):759-65 [17103075.001]
  • [Cites] J Gastrointest Surg. 2007 Sep;11(9):1112-9 [17623263.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1082-8 [14675719.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2069-77 [17440785.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • [Cites] Arch Surg. 2006 May;141(5):460-6; discussion 466-7 [16702517.001]
  • [Cites] Ann Surg. 2004 May;239(5):722-30; discussion 730-2 [15082977.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):933-9 [15151951.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2761-7 [17960603.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1635-41 [18375892.001]
  • (PMID = 19336012.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


51. Weihrauch MR, Stippel D, Fries JW, Arnold D, Bovenschulte H, Coutelle O, Hacker U: Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment. Onkologie; 2008 Sep;31(8-9):464-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment.
  • BACKGROUND: Stage IV colorectal cancer is usually an incurable disease.
  • CASE REPORT: Here, we report the case of a 62-year-old male patient who had been diagnosed with International Union against Cancer (UICC) stage III colon cancer 7 years previously and now presented with a large, irresectable liver metastasis and enlarged perihepatic lymph nodes.
  • CONCLUSION: To our knowledge, this is the first report of a complete pathological response in a patient with irresectable colorectal cancer after intensive chemotherapy/anti-EGFR/ VEGF antibody therapy.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18787354.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil; XELOX
  •  go-up   go-down


52. Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M: Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol; 2008 Sep 15;98(4):263-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination.
  • Medical management with combinations of cytotoxic chemotherapy, and/or biological agents, has resulted in an unprecedented median survival >20 months in patients with Stage IV colorectal cancer.
  • The management of disease limited to the peritoneal cavity has been controversial and at the present time, there is no published data that outlines the impact of these new therapeutic regimens when given to patients with colorectal cancer with metastatic disease confined to the peritoneum.
  • Over the last 5 years, an increasing number of international treatment centers have published their prospective results using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal surface malignancies of colorectal origin and have shown that good long-term results can be achieved with a complete cytoreduction and HIPEC.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Hyperthermia, Induced. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18726889.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


53. Kato T, Miyake Y, Doi T, Hoshi M, Makari Y, Oshima S, Iijima S, Kurokawa E, Kikkawa N: [Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2015-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Third-line treatment of intermittent hepatic arterial infusion for unresectable liver metastases from colorectal cancer].
  • We report 6 cases of liver metastases from colorectal cancer with third-line treatment of intermittent hepatic arterial infusion and systemic chemotherapy for unresectable liver metastases with clinical signification of direct invasion to adjacent organs in Stage IV colorectal cancer.
  • Subjects were 19 consecutive patients who underwent R0 surgery to the primary tumor for colorectal carcinoma, pT4, M1 in 1995-2003.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106508.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


54. Neyns B, Meert V, Vandenbroucke F: Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis. Curr Oncol; 2008 Aug;15(4):196-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.
  • Cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, has activity against colorectal cancer.
  • We report the case of a male patient with stage iv colorectal cancer (crc) and a life-long history of extensive psoriasis.
  • We conclude that, despite its known skin toxicity, cetuximab treatment can be offered to colorectal patients suffering from psoriasis.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2004;43(6):592-3 [15370619.001]
  • [Cites] Am J Hematol. 2002 Sep;71(1):41-4 [12221673.001]
  • [Cites] Bone Marrow Transplant. 2003 Aug;32(4):439-42 [12900783.001]
  • [Cites] Bone Marrow Transplant. 2004 Aug;34(3):281-2 [15156169.001]
  • (PMID = 18769609.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2528307
  • [Keywords] NOTNLM ; Cetuximab / colorectal cancer / psoriasis / skin toxicity
  •  go-up   go-down


55. Lam MS, Kaufman DA, Russin MP: Capecitabine-associated cerebellar ataxia. Am J Health Syst Pharm; 2008 Nov 1;65(21):2032-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: A 65-year-old white woman with stage IV colorectal cancer with liver metastasis was started on a chemotherapy regimen of capecitabine, oxaliplatin, and bevacizumab, given every three weeks.

  • Genetic Alliance. consumer health - Cerebellar Ataxia.
  • Genetic Alliance. consumer health - Ataxia.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945862.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Kattan MW, Gönen M, Jarnagin WR, DeMatteo R, D'Angelica M, Weiser M, Blumgart LH, Fong Y: A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg; 2008 Feb;247(2):282-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer.
  • PURPOSE: To develop a tool for predicting survival after liver resection for patients with stage IV colorectal cancer.
  • PATIENTS AND METHODS: All patients admitted to Memorial Sloan-Kettering Cancer Center (MSKCC) for curative intent for treatment of metastatic disease from colorectal cancer between January 1986 and December 1999 were included.
  • RESULTS: Using nodal status of the primary tumor, disease-free interval, size of the largest metastatic tumor, preoperative carcinoembryonic antigen, bilateral resection, extensive resection (lobectomy or more), gender, number of hepatic tumors, primary cancer site (colon vs. rectum), and age, the nomogram achieved a concordance index of 0.61, statistically significantly greater than chance.
  • [MeSH-major] Colorectal Neoplasms / mortality. Hepatectomy / methods. Liver Neoplasms / mortality. Nomograms

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2008 Jul;248(1):141-2; author reply 142 [18580223.001]
  • (PMID = 18216534.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 75416; United States / NCI NIH HHS / CA / R01 CA/DK80982
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. van der Pool AE, Lalmahomed ZS, de Wilt JH, Eggermont AM, Ijzermans JN, Verhoef C: Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000. J Surg Oncol; 2010 Oct 1;102(5):413-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000.
  • BACKGROUND: The traditional treatment for stage IV colorectal cancer has changed from palliative chemotherapy toward an aggressive multimodality approach.
  • In the current study outcome in patients who underwent surgery for synchronous colorectal liver metastases (CLM) in a single center was evaluated.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:413-418. © 2010 Wiley-Liss, Inc.
  • (PMID = 20544718.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ: Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer; 2008 Sep;7(5):331-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer.
  • We aim to confirm the prognostic value of an inflammation-based prognostic score (the Glasgow Prognostic Score [GPS]) in advanced colorectal cancer, to explore a predictive pattern of plasma cytokines and their gene polymorphisms for clinical outcome, and to investigate which cytokines contribute to GPS.
  • Inflammatory markers were measured at baseline in 52 patients with stage IV colorectal cancer.
  • Toxicity was graded by the National Cancer Institute Common Toxicity Criteria version 2.0.
  • [MeSH-major] Colorectal Neoplasms / mortality. Health Status Indicators. Systemic Inflammatory Response Syndrome / etiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794066.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytokines
  •  go-up   go-down


59. Lee WS, Yun HR, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, Heo JS, Joh JW, Park YS, Kang WK: Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 2):e367-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcomes of hepatic and pulmonary metastases from colorectal carcinoma.
  • BACKGROUND AND AIM: The resection of synchronous or metachronous pulmonary and liver metastasis is an aggressive treatment option for patients with stage IV colorectal cancer and has been shown to yield acceptable long-term survival.
  • We reviewed our experience with colorectal cancer patients with both liver and lung resections to determine the efficacy of surgical resections.
  • METHODS: We performed a single institution, retrospective analysis of all patients who underwent surgical hepatic and pulmonary resection for metastatic colorectal cancer between 1995 and 2004.
  • RESULTS: A total of 32 patients underwent resection of both hepatic and pulmonary metastases secondary to colorectal cancer.
  • CONCLUSION: An aggressive surgical treatment of selected colorectal cancer patients with lung and liver metastases resulted in prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / surgery. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086122.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


60. Akiyama S, Nakayama H, Takami H, Gotoh H, Gotoh Y: Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient. Chemotherapy; 2007;53(6):418-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
  • OBJECTIVE: Combination therapy with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin is widely used for the treatment of metastatic colorectal cancer.
  • We encountered a patient with colorectal carcinoma on HD.
  • He was diagnosed with stage IV colorectal cancer in November 2004.
  • CONCLUSION: These data suggest that the dose-reduced Saltz regimen can be feasible for colorectal cancer patients receiving dialysis as postoperative adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Colorectal Neoplasms / drug therapy. Diabetes Mellitus, Type 1 / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17952001.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


61. Lamberti C, Di Blasi K, Archut D, Fimmers R, Mathiak M, Bollmann M, Vogel J, Kindermann D, Mezger J, Schmidt-Wolf IG, Sauerbruch T: Population-based registration of unselected colorectal cancer patients: five-year survival in the region of Bonn/Rhine-Sieg, Germany. Z Gastroenterol; 2005 Feb;43(2):149-54
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based registration of unselected colorectal cancer patients: five-year survival in the region of Bonn/Rhine-Sieg, Germany.
  • INTRODUCTION: Epidemiological data of colorectal cancer are sparse and often incomplete.
  • Therefore, we initiated a population-based examination of five-year survival of colorectal cancer patients.
  • METHODS: For complete registration, diagnosis and tumour stage of all patients in the region of Bonn/Rhine-Sieg were assessed independently according to reports of medical practitioners and pathologists.
  • According to the UICC classification 18, 26, 23 and 26 % had stage I-IV tumours, respectively; the tumour stage remained unclear in 7 %.
  • Although disease-free survival (DFS) was significantly better for early stage colorectal cancer, OS did not differ significantly between stage I and stage III tumours.
  • DISCUSSION: The high rate of patients with stage IV colorectal cancer and the low proportion of patients receiving adjuvant (radio)-chemotherapy according to international or national consensus recommendations were disappointing.
  • [MeSH-major] Colorectal Neoplasms / mortality. Registries / statistics & numerical data

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15700204.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Aslam MI, Kelkar A, Sharpe D, Jameson JS: Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg; 2010;8(4):305-13
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers.
  • INTRODUCTION: Approximately 20% of patients with colorectal cancer have metastases at the time of presentation.
  • We describe our ten years experience of managing the primary tumours in patients with stage IV colorectal cancer.
  • PATIENTS & METHODS: 920 consecutive patients presenting with stage IV colorectal cancer disease were identified from the Leicester Colorectal Cancer database.
  • The univariate analysis of resection group identified age at presentation, tumour site, tumour stage (pT), lymph nodal stage (pN), complete histological resection, tumour fixity, ASA grade, mode of surgery, post-operative chemotherapy and sites of metastasis as significant factors (p < 0.05) for survival prediction.
  • CONCLUSIONS: Surgical resection of primary tumour for stage IV colorectal cancers is associated with prolonged survival for selected patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Surgical Associates Ltd. All rights reserved.
  • (PMID = 20380899.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Javle M, Hsueh CT: Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol; 2010;3:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations related to gastrointestinal malignancies from 2009 annual meeting of the American Society of Clinical Oncology with the theme of "personalizing cancer care".
  • Adding trastuzumab to chemotherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal growth factor receptor 2.
  • Gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer.
  • Addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage II or III rectal cancer did not improve local tumor response but increased toxicities.
  • Bevacizumab did not provide additional benefit to chemotherapy in adjuvant chemotherapy for stage II or III colon cancer.
  • In patients with resected stage II colon cancer, recurrence score estimated by multigene RT-PCR assay has been shown to provide additional risk stratification.
  • In stage IV colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 2011 Jul 10;29(20):2773-80 [21606427.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1140-6 [15894548.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1898-905 [16219623.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):795-805 [17031648.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):89-95 [18097546.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jun;19(6):855-61 [18503899.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1814-21 [19273709.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3117-25 [19451425.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] World J Surg Oncol. 2009;7:80 [19886993.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • (PMID = 20331897.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2856525
  •  go-up   go-down


64. Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K, Yang D, Danenberg KD, Danenberg PV: Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res; 2005 May 1;11(9):3363-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
  • The purpose of this study was to ascertain if COX-2 gene expression is associated with tumor response in the clinical treatment of colorectal cancer with the fluoropyrimidine-based therapy S-1.
  • EXPERIMENTAL DESIGN: Patients with advanced (stage IV) colorectal cancer were treated with S-1 twice daily based on the patient's body surface area (BSA; BSA < 1.25 m2, 80 mg/d; 1.25 m2 < or = BSA < 1.5 m2, 100 mg/d; BSA > or = 1.5 m2, 120 mg/d) for 28 days followed by a 2-week period rest. mRNA was isolated from paraffin-embedded pretreatment primary tumor specimens and expression levels of COX-2 relative to beta-actin as the internal reference gene were measured using a quantitative reverse transcription-PCR (Taqman) system.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Prostaglandin-Endoperoxide Synthases / genetics. Pyridines / therapeutic use. Tegafur / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867236.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Membrane Proteins; 0 / Pyridines; 0 / RNA, Messenger; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


65. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW: Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs; 2006 Nov;17(10):1227-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
  • Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival.
  • We report a patient with colorectal cancer who developed a rash secondary to bevacizumab that correlated with response.
  • A 40-year-old patient with stage IV colorectal cancer received FOLFOX-4 and bevacizumab, which he tolerated very well except for a skin rash related to bevacizumab.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Exanthema / chemically induced

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Rashes.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075324.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


66. Seledtsov VI, Niza NA, Felde MA, Shishkov AA, Samarin DM, Seledtsova GV, Seledtsov DV: Xenovaccinotherapy for colorectal cancer. Biomed Pharmacother; 2007 Feb-Apr;61(2-3):125-30
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xenovaccinotherapy for colorectal cancer.
  • The objectives of this phase I-II trial were to assess the toxicity, immunological and clinical responses induced in 37 patients with stage IV colorectal cancer by the subcutaneous administration of a xenogenic polyantigenic vaccine (XPV) prepared from disrupted murine melanoma (B16) and carcinoma (LLC) cells.
  • No grade III or IV toxicities, but also laboratory and clinical signs of developing systemic autoimmune disorders were noted in any XPV-treated patient.
  • Collectively the results suggest that xenogenic TAAs are safe to use, able to induce measurable cellular and humoral immune responses, and may be clinically effective in certain colorectal cancer patients.
  • [MeSH-major] Antigens, Neoplasm / therapeutic use. Cancer Vaccines / therapeutic use. Colorectal Neoplasms / drug therapy. Interleukin-2 / therapeutic use
  • [MeSH-minor] Adult. Aged. Animals. Antineoplastic Agents / therapeutic use. Carcinoma. Drug Synergism. Female. Humans. Immunity, Cellular / drug effects. Immunoglobulin G / drug effects. Immunoglobulin G / metabolism. Injections, Subcutaneous. Interferon-gamma / blood. Interferon-gamma / drug effects. Interleukin-4 / blood. Male. Melanoma. Mice. Middle Aged. Neoplasm Staging. Survival Analysis. Th1 Cells / drug effects. Th1 Cells / metabolism. Th2 Cells / drug effects. Th2 Cells / metabolism. Vaccination

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258887.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


67. Houldin A, Lewis FM: Salvaging their normal lives: a qualitative study of patients with recently diagnosed advanced colorectal cancer. Oncol Nurs Forum; 2006 Jul;33(4):719-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvaging their normal lives: a qualitative study of patients with recently diagnosed advanced colorectal cancer.
  • PURPOSE/OBJECTIVES: To describe the experiences of patients living with newly diagnosed stage III or IV colorectal cancer.
  • SETTING: An urban ambulatory cancer center in the northeastern United States.
  • PARTICIPANTS: 14 patients newly diagnosed with stage III or stage IV colorectal cancer.
  • Interviewers asked participants to describe their experiences with the diagnosis and treatment of colorectal cancer.
  • MAIN RESEARCH VARIABLES: Experiences of living with a diagnosis of colorectal cancer, impact on daily living, quality of life, coping strategies used, level of preparedness, and impact on children.
  • The core category that explained study participants' experiences with recently diagnosed colorectal cancer was "salvaging their normal lives."
  • Clinicians who work with patients with cancer should offer support as patients search for meanings to explain this potentially devastating life event.
  • Teaching active coping strategies as patients with advanced cancer struggle to come to terms with the demands of the disease while attempting to live their lives as fully and as normally as possible is important.
  • [MeSH-major] Adaptation, Psychological. Colorectal Neoplasms / complications. Colorectal Neoplasms / psychology. Quality of Life

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858452.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Súarez J, Jiménez J, Vera R, Tarifa A, Balén E, Arrazubi V, Vila J, Lera JM: Stent or surgery for incurable obstructive colorectal cancer: an individualized decision. Int J Colorectal Dis; 2010 Jan;25(1):91-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stent or surgery for incurable obstructive colorectal cancer: an individualized decision.
  • INTRODUCTION: In the setting of stage-IV obstructive colorectal cancer, self-expanding metallic stents (SEMS) placement and palliative surgery may be appropriate options.
  • MATERIALS AND METHODS: From November 2000 to November 2008, 98 patients with incurable stage-IV colorectal cancer were treated with palliative surgery (n=53) or SEMS (n=45).
  • [MeSH-major] Colorectal Neoplasms / surgery. Decision Making. Precision Medicine. Stents

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2007 Jul;142(7):619-23; discussion 623 [17638798.001]
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1301-10 [17486358.001]
  • [Cites] Liver Transpl Surg. 1999 Sep;5(5):366-8 [10477836.001]
  • [Cites] Anesthesiology. 1978 Oct;49(4):233-6 [697075.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1999 Jul;9(3):459-77 [10388861.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Colorectal Dis. 2008 Sep;10(7):668-72 [18266885.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1429-33 [14598426.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1481-7 [16850152.001]
  • (PMID = 19859722.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Read JA, Choy ST, Beale PJ, Clarke SJ: Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer; 2006;55(1):78-85
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.
  • The purpose of this study was to evaluate novel inflammatory and nutritional prognostic factors in patients with advanced colorectal cancer (ACRC).
  • Fifteen (29%) patients were newly diagnosed (stage IV colorectal cancer), and 36 (71%) had received prior chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / mortality. Health Status. Inflammation. Nutritional Status. Severity of Illness Index

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965244.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Albumin; 9007-41-4 / C-Reactive Protein; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


70. Yamamitsu S, Kimura H, Yamada Y, Inui N, Hiyama S, Hirata K, Kimura Y, Shirasaka T: [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1241-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
  • The remedy,especially recent chemotherapy,against colorectal cancer is improving median survival time (MST) of patients with Stage IV advanced colorectal cancer.
  • In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen.
  • These results, although for a limited number of patients, indicated that this may contribute to the extension of survival time of patients with Stage IV advanced colorectal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687205.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


71. Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Escalante E: Outcomes in the management of obstructive unresectable stage IV colorectal cancer. Eur J Surg Oncol; 2010 Dec;36(12):1187-94
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
  • AIM: To analyze short term results and to report survival rates in a series of patients after palliative emergency treatment for obstructive left sided colorectal cancer (CRC) with unresectable synchronous metastases.
  • CONCLUSION: Stenting in palliative stage IV obstructive CRC patients may be less successful as previously thought.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Colostomy. Intestinal Obstruction / etiology. Palliative Care / methods. Stents

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20864304.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol; IFL protocol
  •  go-up   go-down


72. Molnar B, Floro L, Sipos F, Toth B, Sreter L, Tulassay Z: Elevation in peripheral blood circulating tumor cell number correlates with macroscopic progression in UICC stage IV colorectal cancer patients. Dis Markers; 2008;24(3):141-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation in peripheral blood circulating tumor cell number correlates with macroscopic progression in UICC stage IV colorectal cancer patients.
  • AIMS: Cytokeratin(CK) based real-time RT-PCR assays (QRT-PCR) are now available for peripheral blood circulating tumor cell (CTC) evaluations in colorectal cancer(CRC) patients.
  • Results are non-existent for the application of these techniques to the determination of progression and therapy response in Dukes stage D CRC patients.
  • PATIENTS AND METHODS: Each month 30 ml peripheral blood of 30 Dukes D patients (17 with progression) were drawn.
  • Buffy coat was used for immunmagnetic cancer cell isolation and CTC counting.
  • [MeSH-major] Biomarkers, Tumor / blood. Colorectal Neoplasms / pathology. Neoplastic Cells, Circulating

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334735.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3850608
  •  go-up   go-down


73. Field K, Lipton L: Metastatic colorectal cancer-past, progress and future. World J Gastroenterol; 2007 Jul 28;13(28):3806-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colorectal cancer-past, progress and future.
  • The clinical management of metastatic (stage IV) colorectal cancer (CRC) is a common challenge faced by surgeons and physicians.
  • The last decade has seen exciting developments in the management of CRC, with significant improvements in prognosis for patients diagnosed with stage IV disease.
  • Enhanced understanding of the biologic pathways most important in colorectal carcinogenesis has led to a new generation of drugs showing promise in advanced disease.
  • This overview discusses the epidemiology of advanced CRC and currently available therapeutic options including medical, surgical, ablative and novel modalities in the management of metastatic colorectal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy


74. Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, Skondra M, Pissimissis N, Tzonou A, Koutsilieris M: Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol; 2010 Dec 21;16(47):5965-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients.
  • AIM: To develop a multiplex reverse transcription polymerase chain reaction (RT-PCR) method detecting circulating tumor cells in the peripheral blood of colorectal cancer (CRC) patients.
  • The analysis involved determining the detection rates of CEA, CK20 and EGFR transcripts vs disease stage and overall survival.
  • The increasing number of positive detections for CEA, CK20 and EGFR transcripts in each blood sample was positively correlated with Astler-Coller disease stage (P < 0.001) and preoperative serum levels of CEA (P = 0.029) in CRC patients.
  • CONCLUSION: These data suggest that multiplex RT-PCR assay can provide useful information concerning disease stage and overall survival of CRC patients.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Keratin-20 / blood. Receptor, Epidermal Growth Factor / blood. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2005 Apr;29(4):422-8 [15770378.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2329-34 [17914651.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4158-63 [10632355.001]
  • [Cites] Lancet. 2000 Jan 29;355(9201):395-9 [10665570.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1439-44 [10778975.001]
  • [Cites] Ann Surg. 2000 Jul;232(1):58-65 [10862196.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1681-94 [10959054.001]
  • [Cites] Clin Exp Metastasis. 1999;17(10):823-30 [11089880.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):65-73 [11121864.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2523-32 [11289125.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):577-83 [11297251.001]
  • [Cites] Exp Mol Med. 2001 Mar 31;33(1):8-14 [11322488.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):141-6 [11459287.001]
  • [Cites] J Clin Oncol. 2001 Oct 1;19(19):3951-9 [11579116.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8845-50 [11751407.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4080-5 [11751505.001]
  • [Cites] Gut. 2002 Apr;50(4):530-4 [11889075.001]
  • [Cites] Mol Pathol. 2002 Jun;55(3):156-63 [12032226.001]
  • [Cites] Oncol Rep. 2003 Jan-Feb;10(1):217-22 [12469172.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):425-30 [12527944.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):3135-42 [16080577.001]
  • [Cites] Oncol Rep. 2005 Nov;14(5):1199-202 [16211285.001]
  • [Cites] J Mol Diagn. 2005 Nov;7(5):631-7 [16258162.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):297-306 [16391782.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):411-20 [16391796.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):105-12 [16436641.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):385-9 [17058136.001]
  • [Cites] Clin Chem Lab Med. 2006;44(12):1403-9 [17163814.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1092-8 [17200912.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2406-13 [17406027.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1188-203 [17436048.001]
  • [Cites] Clin Chem Lab Med. 2007;45(11):1488-94 [17924845.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):1040-6 [18043108.001]
  • [Cites] J Surg Oncol. 2007 Dec 15;96(8):693-703 [18081153.001]
  • [Cites] Cancer Lett. 2008 May 18;263(2):267-79 [18262345.001]
  • [Cites] Cell Oncol. 2008;30(6):463-71 [18936523.001]
  • [Cites] Jpn J Clin Oncol. 2008 Nov;38(11):770-6 [18845519.001]
  • [Cites] Clin Chem Lab Med. 2009;47(1):1-11 [19055471.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):3945-60 [19192655.001]
  • [Cites] Mol Med. 2009 Mar-Apr;15(3-4):101-14 [19081770.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):272-9 [19103472.001]
  • [Cites] Cancer. 2010 Jun 15;116(12):2913-21 [20336782.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2678-82 [12855647.001]
  • [Cites] Br J Surg. 2003 Aug;90(8):989-95 [12905553.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):324-30; discussion 330-1 [14501498.001]
  • [Cites] Surg Endosc. 2004 Apr;18(4):587-91 [14735340.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Dis Colon Rectum. 1980 Apr;23(3):141-4 [7379666.001]
  • [Cites] Ann Intern Med. 1986 Jan;104(1):66-73 [3510056.001]
  • [Cites] J Cell Biol. 1990 Aug;111(2):567-80 [1696264.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Blood. 1997 Jan 1;89(1):337-44 [8978310.001]
  • [Cites] Exp Hematol. 1997 Jan;25(1):57-65 [8989908.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):343-8 [9516921.001]
  • [Cites] Int J Cancer. 1998 Jun 19;79(3):288-93 [9645353.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3037-43 [9865918.001]
  • [Cites] J Mol Med (Berl). 2004 Nov;82(11):768-74 [15490093.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):436-8 [15637763.001]
  • [Cites] Clin Exp Metastasis. 2004;21(6):495-505 [15679047.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):137-46 [15459772.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(2):155-96 [15941083.001]
  • (PMID = 21157973.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3007112
  •  go-up   go-down


75. Pasz-Walczak G, Salagacka A, Potemski P, Balcerczak E, Kordek R, Mirowski M: Maspin and Nm23-H1 expression in colorectal cancer. Neoplasma; 2010;57(2):95-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin and Nm23-H1 expression in colorectal cancer.
  • The aim of the study was to analyze the expression of Nm23-H1 and maspin proteins in a series of colorectal adenocarcinoma and to assess their applicability as prognostic factors in this type of cancer.
  • 102 specimens of colorectal carcinoma were analyzed by immunohistochemistry with the use of anti-Nm23-H1 and anti-maspin monoclonal antibodies.
  • Medium/high Nm23-H1 cytoplasmic expression level was associated with tubular type of adenocarcinoma with deeper invasion of cancer into intestinal wall (T3, T4) and presence of vascular invasion.
  • Medium/high expression level of maspin was connected uniformly with bad prognostic features: low differentiation of tumors (G3), deeper invasion of cancer (T3, T4) presence of nodular and distant metastases, higher Astler-Coller stage (C1, C2, D) and presence of vascular invasion.
  • Measurement of level and cellular pattern of maspin expression could be valuable for predicting disease course in patients suffering from colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. NM23 Nucleoside Diphosphate Kinases / metabolism. Serpins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099971.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / SERPIN-B5; 0 / Serpins; EC 2.7.4.6 / NME1 protein, human
  •  go-up   go-down


76. Sulzyc-Bielicka V, Domagala P, Majdanik E, Chosia M, Bielicki D, Kladny J, Kaczmarczyk M, Safranow K, Domagala W: Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor. Virchows Arch; 2009 Jun;454(6):695-702
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear thymidylate synthase expression in sporadic colorectal cancer depends on the site of the tumor.
  • Colorectal carcinoma (CRC) is a heterogeneous disease with specific epidemiological, pathological, molecular, and clinical characteristics that depend on the location of the tumor relative to the splenic flexure.
  • In multivariate analysis which included age, sex, Astler-Coller stage, histological grade, and site, only proximal location of the tumor was identified as an independent factor associated with higher TS expression (odds ratio 2.46, 95% confidence interval = 1.29-4.70, p = 0.0062).
  • [MeSH-major] Adenocarcinoma / enzymology. Cell Nucleus / enzymology. Colorectal Neoplasms / enzymology. Intestine, Large / enzymology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):597-602 [11801762.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1810-7 [16971666.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):876-8 [7490328.001]
  • [Cites] Oncology. 1999 Oct;57(3):179-94 [10545786.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1721-7 [16231316.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1304-9 [16160472.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):488-92 [10690528.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] Jpn J Clin Oncol. 2004 Oct;34(10):594-601 [15591457.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1515-20 [9673363.001]
  • [Cites] Ann Intern Med. 1990 Nov 15;113(10):779-88 [2240880.001]
  • [Cites] Cancer Res. 1991 Dec 15;51(24):6668-76 [1720706.001]
  • [Cites] Clin Colorectal Cancer. 2002 Feb;1(4):237-42 [12450422.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1721-8 [11919227.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):643-54 [10100718.001]
  • [Cites] Gut. 1999 Jul;45(1):45-50 [10369703.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):694-701 [17096352.001]
  • [Cites] Oncology. 2006;70(5):366-77 [17179731.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):94-102 [15309465.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Histopathology. 2006 Jun;48(7):787-94 [16722926.001]
  • [Cites] Oncology. 2004;67(2):135-42 [15539918.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):767-72 [17228023.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):529-36 [14752076.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):501-6 [10385139.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Int J Surg Pathol. 2005 Apr;13(2):127-33 [15864374.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] J Surg Oncol. 2004 Dec 15;88(4):261-6 [15565587.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1937-43 [11747337.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):115-26 [17021745.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):19-29 [15956025.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):786-91 [12576451.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13281-5 [9148948.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):395-6 [12560423.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):877-85 [15375535.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):406-12 [12560427.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2832-43 [12065560.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4234-40 [15930362.001]
  • (PMID = 19444465.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


77. Kleespies A, Füessl KE, Seeliger H, Eichhorn ME, Müller MH, Rentsch M, Thasler WE, Angele MK, Kreis ME, Jauch KW: Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis; 2009 Sep;24(9):1097-109
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer.
  • PURPOSE: The benefit of elective primary tumor resection for non-curable stage IV colorectal cancer (CRC) remains largely undefined.
  • METHODS: Using a prospective database, we analyzed potential risk factors in 233 patients, who were electively operated for non-curable stage IV CRC between 1996 and 2002.
  • RESULTS: Patients with colon cancer (CC = 156) and rectal cancer (RC = 77) were comparable with regard to age, sex, comorbidity, American Society of Anesthesiologists score, carcinoembryonic antigen levels, hepatic spread, tumor grade, resection margins, 30-day mortality (CC 5.1%, RC 3.9%) and postoperative chemotherapy. pT4 tumors, carcinomatosis, and non-anatomical resections were more common in colon cancer patients, whereas enterostomies (CC 1.3%, RC 67.5%, p < 0.0001), anastomotic leaks (CC 7.7%, RC 24.2%, p = 0.002), and total surgical complications (CC 19.9%, RC 40.3%, p = 0.001) were more frequent after rectal surgery.
  • Independent determinants of an increased postoperative morbidity were primary rectal cancer, hepatic tumor load >50%, and comorbidity >1 organ.
  • CONCLUSIONS: Palliative resection is associated with a particularly unfavorable outcome in rectal cancer patients presenting with a locally advanced tumor (pT4, expected R2 resection) or an extensive comorbidity, and in all CRC patients who show a hepatic tumor load >50%.
  • [MeSH-major] Colonic Neoplasms / surgery. Elective Surgical Procedures / adverse effects. Palliative Care. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Sep;89(9):1096-102 [12190673.001]
  • [Cites] Colorectal Dis. 2007 Jun;9(5):430-7 [17504340.001]
  • [Cites] Arch Surg. 2000 May;135(5):530-4; discussion 534-5 [10807276.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1646-52 [14668590.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):749-54 [7172942.001]
  • [Cites] J Surg Oncol. 2002 Sep;81(1):3-7 [12210018.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1731-6 [9448628.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2 [12892803.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1099-106 [18181002.001]
  • [Cites] Br J Surg. 2001 Oct;88(10 ):1352-6 [11578291.001]
  • [Cites] BMJ. 2000 Sep 2;321(7260):531-5 [10968812.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):203-13 [12894013.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):262-5 [15019919.001]
  • [Cites] Ann Surg Oncol. 2002 Dec;9(10):954-60 [12464586.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):107-16 [11163503.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):699-709 [19221767.001]
  • [Cites] Dis Colon Rectum. 1990 Oct;33(10):846-50 [1698594.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1142-55 [10971419.001]
  • [Cites] Am J Surg. 2000 Dec;180(6):407-11; discussion 412 [11182388.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1155-60 [16035135.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):156-60 [9075749.001]
  • [Cites] Z Gastroenterol. 2002 Aug;40(8):551-6 [12297977.001]
  • [Cites] Int J Colorectal Dis. 2004 May;19(3):197-202 [14618348.001]
  • [Cites] J Surg Oncol. 2006 Jun 1;93(7):523-8 [16705728.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Dis Colon Rectum. 1988 Nov;31(11):842-7 [2460299.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1116-20 [8869321.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] Arch Surg. 1987 Jun;122(6):640-3 [2437881.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):163-4 [11167862.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S26-34 [17145522.001]
  • [Cites] Gastrointest Endosc. 2000 May;51(5):580-5 [10805846.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1425-9 [9407979.001]
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] Surg Endosc. 2008 Aug;22(8):1818-25 [18095024.001]
  • [Cites] Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60 [6167412.001]
  • [Cites] ANZ J Surg. 2004 Apr;74(4):229-32 [15043733.001]
  • [Cites] Dis Colon Rectum. 1981 Nov-Dec;24(8):606-9 [6172244.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1455-61 [15486741.001]
  • [Cites] Br J Surg. 1995 Oct;82(10):1397-400 [7489177.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):11-4 [9102251.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Endoscopy. 2008 Mar;40(3):184-91 [18322873.001]
  • [Cites] Surgery. 2005 Jan;137(1):42-7 [15614280.001]
  • [Cites] Surg Gynecol Obstet. 1981 Dec;153(6):864-8 [6171042.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):211-7 [15726622.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10 ):1129-77 [15508058.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 [15383792.001]
  • (PMID = 19495779.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Haugstetter AM, Loddenkemper C, Lenze D, Gröne J, Standfuss C, Petersen I, Dörken B, Schmitt CA: Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer; 2010 Aug 10;103(4):505-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular senescence predicts treatment outcome in metastasised colorectal cancer.
  • Whether cancer cell senescence at diagnosis might be predictive for treatment outcome is unknown.
  • METHODS: A senescence index (SI) was developed and used to retrospectively correlate the treatment outcome of 30 UICC stage IV colorectal cancer (CRC) patients with their SI at diagnosis.
  • CONCLUSION: Cancer cell senescence predicts treatment outcome in metastasised CRC.
  • [MeSH-major] Cell Aging. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Cancer Cell. 2010 Mar 16;17(3):262-72 [20227040.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):286-95 [12671667.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):703-10 [12727799.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):1044-8 [8462792.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):3008-19 [9765203.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3761-7 [10446993.001]
  • [Cites] Dev Cell. 2005 Jan;8(1):19-30 [15621527.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2795-803 [15805280.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):907-13 [15829965.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):472-6 [16723993.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):5-20 [17027159.001]
  • [Cites] Oncogene. 2009 Sep 24;28(38):3423-8 [19648962.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):51-7 [20029423.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • [Cites] Lancet Oncol. 2010 Feb;11(2):174-83 [20152769.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1876-83 [11912168.001]
  • (PMID = 20628375.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2939783
  •  go-up   go-down


79. Buffart TE, Coffa J, Hermsen MA, Carvalho B, van der Sijp JR, Ylstra B, Pals G, Schouten JP, Meijer GA: DNA copy number changes at 8q11-24 in metastasized colorectal cancer. Cell Oncol; 2005;27(1):57-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA copy number changes at 8q11-24 in metastasized colorectal cancer.
  • BACKGROUND: C-Myc, a well-known oncogene located on 8q24.12-q24.23, is often amplified and over-expressed in both primary and metastasizing colorectal cancer.
  • In addition, PRL-3 (also known as PTP4A3), a tyrosine phosphatase located on 8q24.3, is amplified in colorectal cancer metastasis.
  • Therefore, the present study aims to correlate DNA copy number status of a series of genes at 8q23-24 in colorectal cancer at high resolution in correlation to metastatic disease.
  • MATERIALS AND METHODS: Thirty-two cases of colorectal cancer, 10 stage B1, 10 B2 and 12 D (Astler-Coller) with their corresponding liver metastasis and one colorectal cell line (colo205, previously analyzed by array-CGH), were included in this study.
  • RESULTS AND DISCUSSION: MLPA results obtained of the colo205 colorectal cell line were comparable with previous array-CGH results, thus validating the MLPA probe mixture.
  • Astler-Coller B1 and B2 colorectal cancers differed significantly in DNA copy number of the genes, MOS (p=0.04), MYC (p=0.007), DDEF1 (p=0.004), PTK2 (p=0.02) and PTP4A3 (p=0.04).
  • When comparing these with Astler-Coller D primary tumors, significant differences were seen for several genes as well (MYC (p<0.000), DDEF1 (p<0.000), SLA (p<0.000), PTK2 (p<0.000), PTP4A3 (p=0.002), and RECQL4 (p=0.01)).
  • When comparing primary Astler-Coller D tumors and their corresponding liver metastases, a similar pattern of gains and losses was observed.
  • CONCLUSION: In addition to c-myc, multiple genes on chromosome 8 differed significantly between primary colorectal cancers with and without liver metastases.
  • [MeSH-major] Chromosomes, Human, Pair 8. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750208.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Immediate-Early Proteins; 0 / Neoplasm Proteins; 0 / Oligonucleotides; 9007-49-2 / DNA; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC4611113
  •  go-up   go-down


80. Seleye-Fubara D, Gbobo I: Pathological study of colorectal carcinoma in adult Nigerians: a study of 45 cases. Niger J Med; 2005 Apr-Jun;14(2):167-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological study of colorectal carcinoma in adult Nigerians: a study of 45 cases.
  • 2001) retrospective study of 45 colorectal carcinomas was carried out the in University of Port Harcourt Teaching Hospital (UPTH) based on age, sex, clinical presentation, anatomical sites, histological types and clinical stages.
  • METHODS: All the histological slides from surgical specimen obtained from the large intestine and diagnosed as colorectal carcinoma were reviewed in Anatomical Pathology Department of UPTH, Port Harcourt.
  • The commonest site of this cancer is the rectum and the least occurred in the transverse colon.
  • Most of our patients presented with advanced cancer of stage IV & III of TNM classification (D and C of Astler-Coller System).
  • CONCLUSION: Colorectal carcinoma is one of commonest malignancies that occurs in young and middle aged in this environment.
  • Patients present when the tumour is in an advanced stage hence poorer prognosis and the ages of the patents is about 10 years earlier than that of Caucasians.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083240.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


81. Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, Kanczuga-Koda L, Sulkowska M: Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol; 2005 Jan 21;11(3):403-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in colorectal cancer.
  • The aim of the present study was to assess the levels of final lipid peroxidation products like malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE) in primary colorectal cancer.
  • METHODS: Investigations were conducted in 81 primary colorectal cancers.
  • As a control, the same amount of sample was collected from macroscopically unchanged colon regions of the most distant location to the cancer.
  • HPLC revealed levels of vitamins C and E and served as a method to detect terminal products of lipid peroxidation in colorectal cancer.
  • -2.65+/-0.48 nmol/g, Adc.G3-2.15+/-0.44 nmol/g, clinical IV stage 4.04+/-0.47 nmol/g, P<0.001 and 4-HNE-Adc.muc.
  • -0.44+/-0.07 nmol/g, Adc.G3-0.44+/-0.10 nmol/g, clinical IV stage 0.52+/-0.11 nmol/g, P<0.001) as well as increase of Cu,Zn-SOD (Adc.muc.
  • -363+/-72 U/g, Adc.G3-318+/-48 U/g, clinical IV stage 421+/-58 U/g, P<0.001), GSH-Px (Adc.muc.
  • -2143+/-623 U/g, Adc.G3-2005+/-591 U/g, clinical IV stage 2467+/-368 U/g, P<0.001) and GSSG-R (Adc.muc.
  • -880+/-194 U/g, Adc.G3-795+/-228 U/g, clinical IV stage 951+/-243 U/g, P<0.001) in primary tumour comparison with normal colon (MDA-1.39+/-0.15 nmol/g, HNE-0.29+/-0.03 nmol/g, Cu, Zn-SOD-117+/-25 U/g, GSH-Px-1723+/-189 U/g, GSSG-R-625+/-112 U/g) especially in mucinous and G3-grade adenocarcinomas as well as clinical IV stage of colorectal cancer.
  • -40+/-14 U/g, clinical IV stage 33+/-18 U/g vs 84+/-17 U/g, P<0.001) as well as a decreased level of reduced glutathione (clinical IV stage 150+/-48 nmol/g vs 167+/-15 nmol/g, P<0.05) and vitamins C and E (vit.
  • C-clinical IV stage 325+/-92 nmol/g vs 513+/-64 nmol/g, P<0.001; vit.
  • E-clinical IV stage 13.3+/-10.3 nmol/g vs 37.5+/-5.2 nmol/g).
  • CONCLUSION: Colorectal carcinogenesis is associated with serious oxidative stress and confirms that gradual advancement of oxidative-antioxidative disorders is followed by progression of colorectal cancer.
  • [MeSH-major] Antioxidants / metabolism. Colorectal Neoplasms / metabolism. Lipid Peroxidation. Oxidoreductases / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637754.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antioxidants; EC 1.- / Oxidoreductases
  • [Other-IDs] NLM/ PMC4205348
  •  go-up   go-down


82. Wieser M, Sauerland S, Arnold D, Schmiegel W, Reinacher-Schick A: Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials. BMC Cancer; 2010;10:309
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials.
  • BACKGROUND: The role of peri-operative chemotherapy in patients with resected stage IV colorectal cancer (CRC) remains to be defined.
  • This study was aimed at evaluating the effectiveness of peri-operative chemotherapy in patients with resected stage IV CRC by performing a meta-analysis of relevant trials.
  • METHODS: We performed a literature search to identify trials comparing patients with stage IV CRC receiving peri-operative chemotherapy and surgery with patients undergoing surgery alone.
  • CONCLUSIONS: This is the first meta-analysis demonstrating the importance of peri-operative chemotherapy in the treatment of resected stage IV CRC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy


83. Etienne-Grimaldi MC, Formento JL, Francoual M, François E, Formento P, Renée N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res; 2008 Aug 1;14(15):4830-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
  • EXPERIMENTAL DESIGN: This study was conducted on 93 stage IV colorectal cancer patients with unresectable measurable liver metastasis receiving 5-FU-leucovorin (56 men and 37 women; 77 cancer deaths).
  • [MeSH-major] Colorectal Neoplasms / genetics. Fluorouracil / administration & dosage. Genes, ras. Leucovorin / administration & dosage. Mutation. Treatment Outcome


84. Balogh A: [Surgical treatment of cancer at the beginning of the third millenium--based on the 2004 Krompecher Memorial Lecture of the Society of Hungarian Oncologists]. Magy Onkol; 2010 Jun;54(2):101-15
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of cancer at the beginning of the third millenium--based on the 2004 Krompecher Memorial Lecture of the Society of Hungarian Oncologists].
  • The author presents a historical overview of cancer surgery of the last century.
  • 1.) Subtotal colectomy (STC) involves an extended resection of the colon over the splenic flexure.
  • In a period of 8 years a total of 72 STCs were performed for the treatment of large bowel obstructions or symptomatic stenosis caused by cancer of the left colon.
  • STC offers: a) one stage treatment for colonic obstruction in emergency surgery, b.) removal of the tumor with sufficient oncological radicality, c.) primary reconstruction of the digestive tract, with a safe ileocolic anastomosis even in emergency cases.
  • 2.) The author reports a total of 108 middle and low third rectal cancer cases operated on by total mesorectal excision (TME) by the method of Heald.
  • The oncological basis of this procedure is the horizontal regional metastatization of rectal cancer.
  • 3.) A total of 154 patients with locally advanced - stage IV - colorectal cancer underwent extended surgery of multivisceral resections as a treatment of cancer process involving adjacent abdominal organs.
  • Surgery was performed to treat advanced cancer of the colon in 112 cases and the one of the rectum in 42 cases.
  • The mortality rate was 7% in the colon cancer group, and 12% in the group of rectal cancer patients.
  • In their tumor-free postoperative period 90% of colon cancer patients and 95% of rectal cancer patients had an improved quality of life.
  • The 5 years survival rate was 40% in the colon group and 22% in the rectal cancer group.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Quality of Life
  • [MeSH-minor] Colonic Neoplasms / surgery. Humans. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576585.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 139
  •  go-up   go-down


85. Secen S, Moljević N, Vuković M, Somer L: [Histopathological finding as a prognostic factor of the surgical treatment outcome in colorectal cancer]. Vojnosanit Pregl; 2010 Aug;67(8):638-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathological finding as a prognostic factor of the surgical treatment outcome in colorectal cancer].
  • BACKGROUND/AIM: Adenocarcinomas of the colon are the most common malignant colorectal tumors.
  • Macroscopic and histopahtological features of colorectal cancer significantly affect its outcome.
  • The histopathological elements analyzed included: the hsitological tumor type grading according to Duke, ie Astler-Coller, and tumor, nodes, metastases (TNM) staging in the examined sample of 100 patients.
  • These factors comprise Astler-Coller-Dukes stage D (revealed in 77.78% patients died), stage IV according TNM classification (T1-4, N0-2, M1), histological structure (poorly diferentiated adenocarcinoma in 85.2% patents died) and type of tumor (mucynous adenocarcinoma was more often present in died, 77.78%).
  • Since phi = 0.000 for four risk factors were formed using discriminant analysus, it was proved their significant influence on the outcome of surgical treatment Discriminant coefficient showed that the greatest influence on surgical treatment were registred in patients with tumor of Astler-Coller-Dukes stage D (0.255), poorly differentiated adenocarcinoma (histological structure) (0.139), mucynous adenocarcinoma (type of tumor) (0.074) and stage IV according to the TNM classification (T1-4, N0-2, M1) (0.39).
  • CONCLUSION: The prognostic factors influencing the outcome of surgery for colorectal carcinoma were defined.
  • Patients with pathohistological finding of Astler-Coller-Dukes stage D, stage IV according to the TNM classification (T1-4, N0-2, M1) and poorly differentiated adenocarcioma have statistically highly significant mortality during the perioperative course of the disease.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845666.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


86. Dakubo JC, Naaeder SB, Tettey Y, Gyasi RK: Colorectal carcinoma: an update of current trends in Accra. West Afr J Med; 2010 May-Jun;29(3):178-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma: an update of current trends in Accra.
  • BACKGROUND: Clinical experience and earlier studies indicate that the number of colorectal cancer cases seen annually in the Accra metropolis is increasing.
  • OBJECTIVE: This study was aimed at providing a current update on colorectal cancer in Accra, Ghana.
  • METHODS: A prospective study of confirmed cases of colorectal cancer diagnosed from January 1997- December 2007.
  • RESULTS: Three hundred and fifty-nine colorectal cancer cases were studied.
  • Rectal bleeding 185(51.1%), abdominal mass 76(21.1%), intestinal obstruction 62(17.3%), intestinal perforation nine (2.5%) and iron deficiency anaemia nine (2.5%) cases were the main presentations.
  • There were 168 (46.8%) rectal and 191(53.2%) colon tumours.
  • The Astler Coller stages of the tumours at diagnosis were C2 84(36.7%), C1 53(22.1%), B2 49(21.4%), D 17(7.4%), B1 14(6.1%) and A 12(5.1%) cases.
  • CONCLUSION: The incidence of colorectal cancer has increased over the last four decades in tandem with an aging population of Accra with adenocarcinoma as the predominant histological type.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology. Rectal Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20665462.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


87. Busić Z, Cupurdija K, Kolovrat M, Cavka V, Cavka M, Patrlj L, Servis D, Kvesić A: Isolated splenic metastasis from colon cancer--case report and literature review. Coll Antropol; 2010 Mar;34 Suppl 1:287-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colon cancer--case report and literature review.
  • In this paper we present a case of 70-year-old man with no history of previous diseases who was first operated under the diagnosis of acute abdomen revealing perforated colon tumor of splenic flexure with no metastases at that time.
  • Primary tumor was classified as Dukes (Astler-Coller)-C2, T4NIMO.
  • The latest follow up, a year after diagnosis of metastasis showed no signs of cancer disease.
  • Review of the literature showed that long term survival and prognosis of isolated splenic colorectal metastasis after splenectomy are rather optimistic, although these are the cases of distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402335.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


88. Cohen AM: What is the best treatment for stage IV colorectal cancer? Ann Surg Oncol; 2005 Aug;12(8):581-2
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the best treatment for stage IV colorectal cancer?
  • [MeSH-major] Colorectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Surg Oncol. 2005 Aug;12(8):637-45 [15965730.001]
  • (PMID = 15959678.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


89. Gil-Bazo I, Díaz-González JA, Rodríguez J, Cortés J, Calvo E, Páramo JA, García-Foncillas J: Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence? World J Gastroenterol; 2005 Oct 14;11(38):6072-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence?
  • [MeSH-major] Colorectal Neoplasms / blood. von Willebrand Factor / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] World J Gastroenterol. 2005 Apr 14;11(14):2166-70 [15810086.001]
  • (PMID = 16273629.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comment; Letter; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / von Willebrand Factor
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC4436739
  •  go-up   go-down


90. Grothey A: Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity. Gastrointest Cancer Res; 2008 Sep;2(5):258-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2004 Dec;240(6):1052-61; discussion 1061-4 [15570210.001]
  • (PMID = 19259312.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2632554
  •  go-up   go-down






Advertisement